<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ELOXATIN- oxaliplatin injection, solution, concentrate </strong><br>sanofi-aventis U.S. LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ELOXATIN safely and effectively.  See full prescribing information for ELOXATIN.  <br><br>ELOXATIN (oxaliplatin) injection for intravenous use <br>Initial U.S. Approval:  2002   </div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">ANAPHYLACTIC REACTIONS</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> to ELOXATIN have been reported, and may occur within minutes of ELOXATIN administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms. (<a href="#S5.1">5.1</a>)</span> </p>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">ANAPHYLACTIC REACTIONS</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> to ELOXATIN have been reported, and may occur within minutes of ELOXATIN administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms. (<a href="#S5.1">5.1</a>)</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ELOXATIN is a platinum-based drug used in combination with infusional 5-fluorouracil /leucovorin, which is indicated for: </p>
<ul>
<li>adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. (<a href="#S1">1</a>)</li>
<li>treatment of advanced colorectal cancer. (<a href="#S1">1</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Administer ELOXATIN in combination with 5-fluorouracil/leucovorin every 2 weeks. (<a href="#S2.1">2.1</a>): <dl>
<dt>–</dt>
<dd>
<span class="Underline">Day 1:</span> ELOXATIN 85 mg/m<span class="Sup">2</span> intravenous infusion in 250–500 mL 5% Dextrose Injection, USP and leucovorin 200 mg/m<span class="Sup">2</span> intravenous infusion in 5% Dextrose Injection, USP both given over 120 minutes at the same time in separate bags using a Y-line, followed by 5-fluorouracil 400 mg/m<span class="Sup">2</span> intravenous bolus given over 2–4 minutes, followed by 5-fluorouracil 600 mg/m<span class="Sup">2</span> intravenous infusion in 500 mL 5% Dextrose Injection, USP (recommended) as a 22-hour continuous infusion.</dd>
<dt>–</dt>
<dd>
<span class="Underline">Day 2:</span>  leucovorin 200 mg/m<span class="Sup">2</span> intravenous infusion over 120 minutes, followed by 5-fluorouracil 400 mg/m<span class="Sup">2</span> intravenous bolus given over 2–4 minutes, followed by 5-fluorouracil 600 mg/m<span class="Sup">2</span> intravenous infusion in 500 mL 5% Dextrose Injection, USP (recommended) as a 22-hour continuous infusion.</dd>
</dl>
</li>
<li>Reduce the dose of ELOXATIN to 75 mg/m<span class="Sup">2</span> (adjuvant setting) or 65 mg/m<span class="Sup">2</span> (advanced colorectal cancer) (<a href="#S2.2">2.2</a>): 	<dl>
<dt>–</dt>
<dd>if there are persistent grade 2 neurosensory events that do not resolve.</dd>
<dt>–</dt>
<dd>after recovery from grade 3/4 gastrointestinal toxicities (despite <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> treatment) or grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or grade 3/4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. Delay next dose until <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> ≥1.5 × 10<span class="Sup">9</span>/L and platelets ≥75 × 10<span class="Sup">9</span>/L.</dd>
</dl>
</li>
<li>For patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;30 mL/min), the initial recommended dose is 65 mg/m<span class="Sup">2</span>. (<a href="#S2.2">2.2</a>)</li>
<li>Discontinue ELOXATIN if there are persistent Grade 3 neurosensory events. (<a href="#S2.2">2.2</a>)</li>
<li>Never prepare a final dilution with a sodium chloride solution or other chloride-containing solutions. (<a href="#S2.3">2.3</a>)</li>
</ul></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Single-use vials of 50 mg or 100 mg oxaliplatin as a sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL. (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to ELOXATIN or other platinum compounds. (<a href="#S4">4</a>, <a href="#S5.1">5.1</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span>:  Monitor for development of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, pruritis, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. (<a href="#S5.1">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span>:  Reduce the dose or discontinue ELOXATIN if necessary. (<a href="#S5.2">5.2</a>)</li>
<li>Pulmonary Toxicity:  May need to discontinue ELOXATIN until <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span> or <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span> are excluded. (<a href="#S5.3">5.3</a>)</li>
<li>Hepatotoxicity:  Monitor liver function tests. (<a href="#S5.4">5.4</a>)</li>
<li>Pregnancy. Fetal harm can occur when administered to a pregnant woman.  Women should be apprised of the potential harm to the fetus. (<a href="#S5.5">5.5</a>, <a href="#S8.1">8.1</a>)</li>
</ul></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul><li>Most common adverse reactions (incidence ≥ 40%) were <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">peripheral sensory neuropathy</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, increase in transaminases and alkaline phosphatase, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>. Other adverse reactions, including serious adverse reactions, have been reported. (<a href="#S6.1">6.1</a>)</li></ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis U.S. LLC at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 2/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">ANAPHYLACTIC REACTIONS</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE and ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dose Modification Recommendations</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Preparation of Infusion Solution</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Neurologic Toxicity</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Pulmonary Toxicity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Hepatotoxicity</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Use in Pregnancy </a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Recommended Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-9.1" class="toc"></a></h2>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Combination Adjuvant Therapy with ELOXATIN and Infusional 5-fluorouracil/leucovorin in Patients with Colon Cancer</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Combination Therapy with ELOXATIN and 5-fluorouracil/leucovorin in Patients Previously Untreated for Advanced Colorectal Cancer</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Combination Therapy with ELOXATIN and 5-fluorouracil/leucovorin in Previously Treated Patients with Advanced Colorectal Cancer</a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16. HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1	How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage</a></h2>
<h2><a href="#section-15.3" class="toc">16.3 Handling and Disposal</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">ANAPHYLACTIC REACTIONS</span></h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> to ELOXATIN have been reported, and may occur within minutes of ELOXATIN administration.  Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>].</span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">ELOXATIN, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: </p>
<ul>
<li>adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. </li>
<li>treatment of advanced colorectal cancer.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE and ADMINISTRATION</h1>
<p class="First">ELOXATIN (oxaliplatin injection) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents.  Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosage</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1"></a><p></p>
<h3></h3>
<p class="First">Administer ELOXATIN in combination with 5-fluorouracil/leucovorin every 2 weeks. For advanced disease, treatment is recommended until disease progression or unacceptable toxicity. For adjuvant use, treatment is recommended for a total of 6 months (12 cycles):</p>
<p>Day 1:  ELOXATIN 85 mg/m<span class="Sup">2</span> intravenous infusion in 250–500 mL 5% Dextrose injection, USP and leucovorin 200 mg/m<span class="Sup">2</span> intravenous infusion in 5% Dextrose Injection, USP both given over 120 minutes at the same time in separate bags using a Y-line, followed by 5-fluorouracil 400 mg/m<span class="Sup">2</span> intravenous bolus given over 2–4 minutes, followed by 5-fluorouracil 600 mg/m<span class="Sup">2</span> intravenous infusion in 500 mL 5% Dextrose Injection, USP (recommended) as a 22-hour continuous infusion.</p>
<p>Day 2:  Leucovorin 200 mg/m<span class="Sup">2</span> intravenous infusion over 120 minutes, followed by 5-fluorouracil 400 mg/m<span class="Sup">2</span> intravenous bolus given over 2–4 minutes, followed by 5-fluorouracil 600 mg/m<span class="Sup">2</span> intravenous infusion in 500 mL 5% Dextrose Injection, USP (recommended) as a 22-hour continuous infusion.</p>
<p><span class="Bold">Figure 1</span></p>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3c740b43-f396-4998-bc66-6964a21f7161&amp;name=eloxatin-01.jpg"></div>
<p>The administration of ELOXATIN does not require prehydration. Premedication with antiemetics, including 5-HT<span class="Sub">3</span> blockers with or without dexamethasone, is recommended.</p>
<p>For information on 5-fluorouracil and leucovorin, see the respective package inserts.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dose Modification Recommendations</h2>
<p class="First">Prior to subsequent therapy cycles, patients should be evaluated for clinical toxicities and recommended laboratory tests <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>. Prolongation of infusion time for ELOXATIN from 2 hours to 6 hours may mitigate acute toxicities. The infusion times for 5-fluorouracil and leucovorin do not need to be changed.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline">Adjuvant Therapy in Patients with Stage III Colon Cancer</span></p>
<p><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span> and other toxicities were graded using the NCI CTC scale version 1 <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>].</span></p>
<p>For patients who experience persistent Grade 2 neurosensory events that do not resolve, a dose reduction of ELOXATIN to 75 mg/m<span class="Sup">2</span> should be considered. For patients with persistent Grade 3 neurosensory events, discontinuing therapy should be considered. The infusional 5-fluorouracil/leucovorin regimen need not be altered.  </p>
<p>A dose reduction of ELOXATIN to 75 mg/m<span class="Sup">2</span> and infusional 5-fluorouracil to 300  mg/m<span class="Sup">2</span> bolus and 500 mg/m<span class="Sup">2</span> 22 hour infusion is recommended for patients after recovery from grade 3/4 gastrointestinal (despite <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> treatment) or grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or grade 3/4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. The next dose should be delayed until: <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> ≥1.5 × 10<span class="Sup">9</span>/L and platelets ≥75 × 10<span class="Sup">9</span>/L.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline">Dose Modifications in Therapy in Previously Untreated and Previously Treated Patients with Advanced Colorectal Cancer</span></p>
<p><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span> was graded using a study-specific <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> scale <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>. Other toxicities were graded by the NCI CTC, Version 2.0.</p>
<p>For patients who experience persistent Grade 2 neurosensory events that do not resolve, a dose reduction of ELOXATIN to 65 mg/m<span class="Sup">2</span> should be considered. For patients with persistent Grade 3 neurosensory events, discontinuing therapy should be considered. The 5-fluorouracil/leucovorin regimen need not be altered.</p>
<p>A dose reduction of ELOXATIN to 65 mg/m<span class="Sup">2</span> and 5-fluorouracil by 20% (300 mg/m<span class="Sup">2</span> bolus and 500 mg/m<span class="Sup">2</span> 22-hour infusion) is recommended for patients after recovery from grade 3/4 gastrointestinal (despite <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> treatment) or grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or grade 3/4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. The next dose should be delayed until:  <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> ≥1.5 × 10<span class="Sup">9</span>/L and platelets ≥75 × 10<span class="Sup">9</span>/L.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.3"></a><p></p>
<p class="First"><span class="Italics Underline">Dose Modifications in Therapy for Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>In patients with normal renal function or mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the recommended dose of ELOXATIN is 85 mg/m<span class="Sup">2</span>. In patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the initial recommended ELOXATIN dose should be reduced to 65 mg/m<span class="Sup">2</span><span class="Italics"> [see<a href="#S8.6"> Use in Specific Populations (8.6) </a>and<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Preparation of Infusion Solution</h2>
<p class="First">Do not freeze and protect from light the concentrated solution.<br><span class="Bold">A final dilution must never be performed with a sodium chloride solution or other chloride-containing solutions.</span><br>The solution must be further diluted in an infusion solution of 250-500 mL of 5% Dextrose Injection, USP.   <br>After dilution with 250-500 mL of 5% Dextrose Injection, USP, the shelf life is 6 hours at room temperature [20-25°C (68-77°F)] or up to 24 hours under refrigeration [2-8°C (36-46°F)]. <br>After final dilution, protection from light is not required.</p>
<br><p>ELOXATIN is incompatible in solution with alkaline medications or media (such as basic solutions of 5-fluorouracil) and must not be mixed with these or administered simultaneously through the same infusion line. <span class="Bold">The infusion line should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> with 5% Dextrose Injection, USP prior to administration of any concomitant medication.</span><br>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration and discarded if present.</p>
<p>Needles or intravenous administration sets containing aluminum parts that may come in contact with ELOXATIN should not be used for the preparation or mixing of the drug. Aluminum has been reported to cause degradation of platinum compounds.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">ELOXATIN is supplied in single-use vials containing 50 mg or 100 mg of oxaliplatin as a sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">ELOXATIN should not be administered to patients with a history of known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to ELOXATIN or other platinum compounds <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">See <a href="#BOX">boxed warning</a></p>
<p>Grade 3/4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, including anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, to ELOXATIN has been observed in 2–3% of colon cancer patients.  These <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> which can be fatal, can occur within minutes of administration and at any cycle, and were similar in nature and severity to those reported with other platinum-containing compounds, such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and, rarely, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.  The symptoms associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> reported in the previously untreated patients were <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> of the face, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> associated with oxaliplatin infusion, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pains</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.  These reactions are usually managed with standard epinephrine, corticosteroid, antihistamine therapy, and require discontinuation of therapy. Rechallenge is contraindicated in these patients<span class="Italics"> [see<a href="#S4"> Contraindications (4)</a>]</span>. Drug-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> associated with platinum compounds from <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Neurologic Toxicity</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></span></p>
<p>ELOXATIN is associated with two types of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>:</p>
<p><span class="Bold">An acute, reversible, primarily peripheral, <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">sensory neuropathy</span> that is of early onset, occurring within hours or one to two days of dosing, that resolves within 14 days, and that frequently recurs with further dosing.</span>The symptoms may be precipitated or exacerbated by exposure to <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> temperature or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> objects and they usually present as transient <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span> and <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span> in the hands, feet, perioral area, or throat.  <span class="product-label-link" type="condition" conceptid="4339090" conceptname="Trismus">Jaw spasm</span>, abnormal tongue sensation, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, and a feeling of <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest pressure</span> have also been observed.  The acute, reversible pattern of <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">sensory neuropathy</span> was observed in about 56% of study patients who received ELOXATIN with 5-fluorouracil/leucovorin. In any individual cycle acute <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> was observed in approximately 30% of patients. In adjuvant patients the median cycle of onset for grade 3 <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">peripheral sensory neuropathy</span> was 9 in the previously treated patients the median number of cycles administered on the ELOXATIN with 5-fluorouracil/leucovorin combination arm was 6.</p>
<p>An acute syndrome of pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span> seen in 1–2% (grade 3/4) of patients previously untreated for advanced colorectal cancer, and the previously treated patients, is characterized by subjective sensations of <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, without any <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> or <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> (no <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span> or <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>). Ice (<span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> prophylaxis) should be avoided during the infusion of ELOXATIN because <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> temperature can exacerbate acute neurological symptoms.</p>
<p><span class="Bold">A persistent (&gt;14 days), primarily peripheral, <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">sensory neuropathy</span> that is usually characterized by <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesias</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesias</span>, but may also include deficits in proprioception that can interfere with daily activities (e.g., writing, buttoning, swallowing, and difficulty walking from impaired proprioception).</span>  These forms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> occurred in 48% of the study patients receiving ELOXATIN with 5-fluorouracil/leucovorin.  Persistent <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> can occur without any prior acute <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> event.  The majority of the patients (80%) who developed grade 3 persistent <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> progressed from prior Grade 1 or 2 events.  These symptoms may improve in some patients upon discontinuation of ELOXATIN.</p>
<p>In the adjuvant colon cancer trial, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> was graded using a prelisted module derived from the Neuro-Sensory section of the National Cancer Institute Common Toxicity Criteria (NCI CTC) scale, Version 1, as follows:</p>
<table width="75%">
<caption><span>Table 1 - NCI CTC Grading for <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span> in Adjuvant Patients</span></caption>
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="70%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="bottom">Grade</th>
<th class="Rrule" align="center" valign="top">Definition</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Grade 0</td>
<td class="Rrule" align="left">No change or none</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 1</td>
<td class="Rrule" align="left">Mild <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, loss of deep tendon reflexes</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 2</td>
<td class="Rrule" align="left">Mild or moderate objective <span class="product-label-link" type="condition" conceptid="4141128" conceptname="Absence of sensation">sensory loss</span>, moderate <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 3</td>
<td class="Rrule" align="left">Severe objective <span class="product-label-link" type="condition" conceptid="4141128" conceptname="Absence of sensation">sensory loss</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> that interfere with function</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Grade 4</td>
<td class="Rrule" align="left">Not applicable</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">Peripheral sensory neuropathy</span> was reported in adjuvant patients treated with the ELOXATIN combination with a frequency of 92% (all grades) and 13% (grade 3).  At the 28-day follow-up after the last treatment cycle, 60% of all patients had any grade (Grade 1=40%, Grade 2=16%, Grade 3=5%) <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">peripheral sensory neuropathy</span> decreasing to 39% at 6 months follow-up (Grade 1=31%, Grade 2=7%, Grade 3=1%) and 21% at 18 months of follow-up (Grade 1=17%, Grade 2=3%, Grade 3=1%).</p>
<p>In the advanced colorectal cancer studies, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> was graded using a study-specific <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> scale, which was different from the NCI CTC scale, Version 2.0 (see below).</p>
<table width="65%">
<caption><span>Table 2 - Grading Scale for <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesias</span>/<span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">Dysesthesias</span> in Advanced Colorectal Cancer Patients</span></caption>
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="75%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Grade</th>
<th class="Lrule Rrule" align="center">Definition</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left">Grade 1</td>
<td class="Lrule Rrule" align="left">Resolved and did not interfere with functioning</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Grade 2</td>
<td class="Lrule Rrule" align="left">Interfered with function but not daily activities</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Grade 3	</td>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> or functional impairment that interfered with daily activities</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Grade 4</td>
<td class="Lrule Rrule" align="left">Persistent impairment that is disabling or life-threatening</td>
</tr>
</tbody>
</table>
<p>Overall, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> was reported in patients previously untreated for advanced colorectal cancer in 82% (all grades) and 19% (grade 3/4), and in the previously treated patients in 74% (all grades) and 7% (grade 3/4) events. Information regarding reversibility of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> was not available from the trial for patients who had not been previously treated for colorectal cancer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible Posterior Leukoencephalopathy Syndrome</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible Posterior Leukoencephalopathy Syndrome</span> (RPLS, also known as PRES, Posterior Reversible <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span> Syndrome) has been observed in clinical trials (&lt; 0.1%) and postmarketing experience.   Signs and symptoms of RPLS could be <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, altered mental functioning, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span> from blurriness to <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, associated or not with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span><span class="Italics"> [see<a href="#S6.2"> Adverse  Reactions (6.2)</a>]</span>. Diagnosis of RPLS is based upon confirmation by brain imaging.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Pulmonary Toxicity</h2>
<p class="First">ELOXATIN has been associated with <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span> (&lt;1% of study patients), which may be fatal. The combined incidence of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> was 7.4% (any grade) and &lt;1% (grade 3) with no grade 4 events in the ELOXATIN plus infusional 5-fluorouracil/leucovorin arm compared to 4.5% (any grade) and no grade 3 and 0.1% grade 4 events in the infusional 5-fluorouracil/leucovorin alone arm in adjuvant colon cancer patients. In this study, one patient died from <span class="product-label-link" type="condition" conceptid="4279553" conceptname="Eosinophilic asthma">eosinophilic pneumonia</span> in the ELOXATIN combination arm. The combined incidence of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> and <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> was 43% (any grade) and 7% (grade 3 and 4) in the ELOXATIN plus 5-fluorouracil/leucovorin arm compared to 32% (any grade) and 5% (grade 3 and 4) in the irinotecan plus 5-fluorouracil/leucovorin arm of unknown duration for patients with previously untreated colorectal cancer. In case of unexplained respiratory symptoms such as non-<span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">productive cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, crackles, or radiological pulmonary infiltrates, ELOXATIN should be discontinued until further pulmonary investigation excludes <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span> or <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Hepatotoxicity</h2>
<p class="First">Hepatotoxicity as evidenced in the adjuvant study, by increase in transaminases (57% vs. 34%) and alkaline phosphatase (42% vs. 20%) was observed more commonly in the ELOXATIN combination arm than in the control arm. The incidence of increased bilirubin was similar on both arms. Changes noted on liver biopsies include: <span class="product-label-link" type="condition" conceptid="4055720" conceptname="Vascular hemostatic disease">peliosis</span>, <span class="product-label-link" type="condition" conceptid="4263948" conceptname="Nodular hyperplasia">nodular regenerative hyperplasia</span> or sinusoidal alterations, perisinusoidal <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>, and veno-occlusive lesions. Hepatic <span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">vascular disorders</span> should be considered, and if appropriate, should be investigated in case of abnormal liver function test results or <span class="product-label-link" type="condition" conceptid="192680" conceptname="Portal hypertension">portal hypertension</span>, which cannot be explained by liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> <span class="Italics">[see <a href="#S6.1">Clinical Trials Experience (6.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Use in Pregnancy </h2>
<p class="First">Pregnancy Category D</p>
<p>ELOXATIN may cause fetal harm when administered to a pregnant woman.  There are no adequate and well-controlled studies of ELOXATIN in pregnant women.  Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with ELOXATIN. <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Recommended Laboratory Tests</h2>
<p class="First">Standard monitoring of the white blood cell count with differential, hemoglobin, platelet count, and blood chemistries (including ALT, AST, bilirubin and creatinine) is recommended before each ELOXATIN cycle <span class="Italics">[see <a href="#S2">Dosage and Administration (2)</a>].</span></p>
<p>There have been reports while on study and from post-marketing surveillance of prolonged <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time and INR occasionally associated with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> in patients who received ELOXATIN plus 5-fluorouracil/leucovorin while on anticoagulants.  Patients receiving ELOXATIN plus 5-fluorouracil/leucovorin and requiring oral anticoagulants may require closer monitoring. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the label:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> [See <span class="Italics"><a href="#box">Boxed Warning</a>, <a href="#s5.1">Warnings and Precautions (5.1)</a></span>.]</li>
<li><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span> [See <span class="Italics"><a href="#s5.2">Warnings and Precautions (5.2)</a></span>.]</li>
<li>Pulmonary Toxicities [See <span class="Italics"><a href="#s5.3">Warnings and Precautions (5.3)</a></span>.]</li>
<li>Hepatotoxicity [See <span class="Italics"><a href="#s5.4">Warnings and Precautions (5.4)</a></span>.]</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>More than 1100 patients with stage II or III colon cancer and more than 4,000 patients with advanced colorectal cancer have been treated in clinical studies with ELOXATIN. The most common adverse reactions in patients with stage II or III colon cancer receiving adjuvant therapy were <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">peripheral sensory neuropathy</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, increase in transaminases and alkaline phosphatase, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>. The most common adverse reactions in previously untreated and treated patients were peripheral sensory neuropathies, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> <span class="Italics">[see <a href="#S5">Warnings and Precautions (5)</a>].</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline">Combination Adjuvant Therapy with ELOXATIN and Infusional 5-fluorouracil/leucovorin in Patients with Colon Cancer</span></p>
<p>One thousand one hundred and eight patients with stage II or III colon cancer, who had undergone complete resection of the primary tumor, have been treated in a clinical study with ELOXATIN in combination with infusional 5-fluorouracil/leucovorin <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>].</span>  The incidence of grade 3 or 4 adverse reactions was 70% on the ELOXATIN combination arm, and 31% on the infusional 5-fluorouracil/leucovorin arm. The adverse reactions in this trial are shown in the tables below. Discontinuation of treatment due to adverse reactions occurred in 15% of the patients receiving ELOXATIN and infusional 5-fluorouracil/leucovorin. Both 5-fluorouracil/leucovorin and ELOXATIN are associated with gastrointestinal or hematologic adverse reactions. When ELOXATIN is administered in combination with infusional 5-fluorouracil/leucovorin, the incidence of these events is increased.</p>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> within 28 days of last treatment, regardless of causality, was 0.5% (n=6) in both the ELOXATIN combination and infusional 5-fluorouracil/leucovorin arms, respectively. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> within 60 days from initiation of therapy were 0.3% (n=3) in both the ELOXATIN combination and infusional 5-fluorouracil/leucovorin arms, respectively. On the ELOXATIN combination arm, 3 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were due to <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>/<span class="product-label-link" type="condition" conceptid="40484176" conceptname="Neutropenic sepsis">neutropenic sepsis</span>, 2 from intracerebral <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and one from <span class="product-label-link" type="condition" conceptid="4279553" conceptname="Eosinophilic asthma">eosinophilic pneumonia</span>. On the 5-fluorouracil/leucovorin arm, one <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was due to <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, 2 from Steven-Johnson Syndrome (1 patient also had <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>), 1 unknown cause, 1 anoxic <span class="product-label-link" type="condition" conceptid="443454" conceptname="Cerebral infarction">cerebral infarction</span> and 1 probable abdominal aorta rupture.</p>
<p>The following table provides adverse reactions reported in the adjuvant therapy colon cancer clinical trial <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span> by body system and decreasing order of frequency in the ELOXATIN and infusional 5-fluorouracil/leucovorin arm for events with overall incidences ≥ 5% and for NCI grade 3/4 events with incidences ≥ 1%. </p>
<table width="100%">
<caption><span>Table 3 - Adverse Reactions Reported in Patients with Colon Cancer receiving Adjuvant Treatment (≥5% of all patients and with ≥1% NCI Grade 3/4 events)</span></caption>
<col align="left" valign="bottom" width="24%">
<col align="center" valign="bottom" width="19%">
<col align="center" valign="bottom" width="19%">
<col align="center" valign="bottom" width="19%">
<col align="center" valign="bottom" width="19%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="2">ELOXATIN + 5-FU/LV<br>N=1108</th>
<th class="Botrule Rrule" align="center" colspan="2">5-FU/LV<br>N=1111</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="left">Adverse reaction<br>(WHO/Pref)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Includes <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> related to the catheter</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Any Event</td>
<td class="Rrule" align="center">100</td>
<td class="Rrule" align="center">70</td>
<td class="Rrule" align="center">99</td>
<td class="Rrule" align="center">31</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="5"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span>/Immunology</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reaction</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="5"><span class="Bold">Constitutional Symptoms/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">44</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">38</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="5"><span class="Bold">Dermatology/Skin</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin Disorder</span></td>
<td class="Rrule" align="center">32</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">36</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection Site Reaction</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="5"><span class="Bold">Gastrointestinal</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">74</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">61</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">56</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">48</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">47</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Rrule" align="center">42</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">40</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="5"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>/<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="5"><span class="Bold">Neurology</span></td></tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Overall <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">Peripheral Sensory Neuropathy</span></td>
<td class="Rrule" align="center">92</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
</tbody>
</table>
<p>The following table provides adverse reactions reported in the adjuvant therapy colon cancer clinical trial <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span> by body system and decreasing order of frequency in the ELOXATIN and infusional 5-fluorouracil/leucovorin arm for events with overall incidences ≥ 5% but with incidences &lt;1% NCI grade 3/4 events. </p>
<table width="75%">
<caption><span>Table 4 - Adverse Reactions Reported in Patients with Colon Cancer receiving Adjuvant Treatment (≥ 5% of all patients, but with &lt;1% NCI Grade 3/4 events)</span></caption>
<col align="left" valign="bottom" width="34%">
<col align="center" valign="bottom" width="33%">
<col align="center" valign="bottom" width="33%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center">Eloxatin + 5-FU/LV<br>N=1108</th>
<th class="Botrule Rrule" align="center">5-FU/LV<br>N=1111</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Adverse reaction<br> (WHO/Pref)</th>
<th class="Rrule" align="center" valign="top">All Grades (%)</th>
<th class="Rrule" align="center" valign="top">All Grades (%)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span>/Immunology</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">8</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="3"><span class="Bold">Constitutional Symptoms/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>/Ocular/Visual</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">12</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Increase</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">10</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">15</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="379814" conceptname="Dislocation of lacrimal gland">Lacrimation Abnormal</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">12</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="3"><span class="Bold">Dermatology/Skin</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Rrule" align="center">30</td>
<td class="Rrule" align="center">28</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="3"><span class="Bold">Gastrointestinal</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">19</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Perversion</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="3"><span class="Bold">Metabolic</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Phosphate Alkaline increased</td>
<td class="Rrule" align="center">42</td>
<td class="Rrule" align="center">20</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="3"><span class="Bold">Neurology</span></td></tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">Sensory Disturbance</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">1</td>
</tr>
</tbody>
</table>
<p>Although specific events can vary, the overall frequency of adverse reactions was similar in men and women and in patients &lt;65 and ≥65 years. However, the following grade 3/4 events were more common in females: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. In patients ≥65 years old, the incidence of grade 3/4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> was higher than in younger patients. Insufficient subgroup sizes prevented analysis of safety by race. The following additional adverse reactions, were reported in ≥2% and &lt;5% of the patients in the ELOXATIN and infusional 5-fluorouracil/leucovorin combination arm (listed in decreasing order of frequency): <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>.</p>
<p>The number of patients who developed secondary malignancies was similar; 62 in the ELOXATIN combination arm and 68 in the infusional 5-fluorouracil/leucovorin arm. An exploratory analysis showed that the number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to secondary malignancies was 1.96% in the ELOXATIN combination arm and 0.98% in infusional 5-fluorouracil/leucovorin arm.  In addition, the number of cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> was 1.4% in the ELOXATIN combination arm as compared to 0.7% in the infusional 5-fluorouracil/leucovorin arm. Clinical significance of these findings is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline">Patients Previously Untreated for Advanced Colorectal Cancer</span></p>
<p>Two hundred and fifty-nine patients were treated in the ELOXATIN and 5-fluorouracil/leucovorin combination arm of the randomized trial in patients previously untreated for advanced colorectal cancer <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. The adverse reaction profile in this study was similar to that seen in other studies and the adverse reactions in this trial are shown in the tables below.<br>Both 5-fluorouracil and ELOXATIN are associated with gastrointestinal and hematologic adverse reactions. When ELOXATIN is administered in combination with 5-fluorouracil, the incidence of these events is increased.</p>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> within 30 days of treatment in the previously untreated for advanced colorectal cancer study, regardless of causality, was 3% with the ELOXATIN and 5-fluorouracil/leucovorin combination, 5% with irinotecan plus 5-fluorouracil/leucovorin, and 3% with ELOXATIN plus irinotecan. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> within 60 days from initiation of therapy were 2.3% with the ELOXATIN and 5-fluorouracil/leucovorin combination, 5.1% with irinotecan plus 5-fluorouracil/leucovorin, and 3.1% with ELOXATIN plus irinotecan. <br>The following table provides adverse reactions reported in the previously untreated for advanced colorectal cancer study <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span> by body system and decreasing order of frequency in the ELOXATIN and 5-fluorouracil/leucovorin combination arm for events with overall incidences ≥5% and for grade 3/4 events with incidences ≥1%.</p>
<table width="100%">
<caption><span>Table 5 – Adverse Reactions Reported in Patients Previously Untreated for Advanced Colorectal Cancer Clinical Trial (≥5% of all patients and with ≥1% NCI Grade 3/4 events)</span></caption>
<col align="left" valign="bottom" width="22%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="2">ELOXATIN + 5-FU/LV<br>N=259</th>
<th class="Botrule Rrule" align="center" colspan="2">irinotecan + 5-FU/LV<br>N=256</th>
<th class="Botrule Rrule" align="center" colspan="2">ELOXATIN + irinotecan<br>N=258</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Adverse reaction<br>(WHO/Pref)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
<th class="Rrule" align="center">All Grades <br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Not otherwise specified</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>Absolute neutrophil count</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Any Event</td>
<td class="Rrule" align="center">99</td>
<td class="Rrule" align="center">82</td>
<td class="Rrule" align="center">98</td>
<td class="Rrule" align="center">70</td>
<td class="Rrule" align="center">99</td>
<td class="Rrule" align="center">76</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="7"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span>/Immunology</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="7"><span class="Bold">Cardiovascular</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="7"><span class="Bold">Constitutional Symptoms/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>/Ocular/Visual</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">70</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">58</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">66</td>
<td class="Rrule" align="center">16</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Rrule" align="center">29</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">39</td>
<td class="Rrule" align="center">10</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">Vision abnormal</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuralgia</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="7"><span class="Bold">Dermatology/Skin</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin reaction</span> – hand/foot</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="7"><span class="Bold">Gastrointestinal</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">71</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">67</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">83</td>
<td class="Rrule" align="center">19</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">56</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">65</td>
<td class="Rrule" align="center">29</td>
<td class="Rrule" align="center">76</td>
<td class="Rrule" align="center">25</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">41</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">43</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">64</td>
<td class="Rrule" align="center">23</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Rrule" align="center">38</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Rrule" align="center">35</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">32</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>-colostomy</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Gastrointestinal NOS<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="7"><span class="Bold">Hematology/<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> normal ANC<a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a>
</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> low ANC<a href="#footnote-3" class="Sup">†</a>
</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphopenia</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">11</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="7"><span class="Bold">Hepatic/Metabolic/Laboratory/Renal</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary frequency</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="7"><span class="Bold">Neurology</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Overall <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></td>
<td class="Rrule" align="center">82</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">69</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesias</span></td>
<td class="Rrule" align="center">77</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">62</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Pharyngo-laryngeal <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesias</span></td>
<td class="Rrule" align="center">38</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Neuro-sensory</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Neuro NOS<a href="#footnote-2" class="Sup">*</a>
</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="7"><span class="Bold">Pulmonary</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="center">35</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">Hiccups</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
</tr>
</tbody>
</table>
<p>The following table provides adverse reactions reported in the previously untreated for advanced colorectal cancer study <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>] </span>by body system and decreasing order of frequency in the ELOXATIN and 5-fluorouracil/leucovorin combination arm for events with overall incidences ≥5% but with incidences &lt;1% NCI Grade 3/4 events.</p>
<table width="75%">
<caption><span>Table 6 - Adverse Reactions Reported in Patients Previously Untreated for Advanced Colorectal Cancer Clinical Trial (≥5% of all patients but with &lt; 1% NCI Grade 3/4 events)</span></caption>
<col align="left" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center">ELOXATIN + 5-FU/LV<br>N=259</th>
<th class="Botrule Rrule" align="center">irinotecan + 5-FU/LV<br>N=256</th>
<th class="Botrule Rrule" align="center">ELOXATIN + irinotecan<br>N=258</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="center">Adverse reaction<br>(WHO/Pref)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Absolute neutrophil count</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="4"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span>/Immunology</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Rhinitis allergic</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4"><span class="Bold">Cardiovascular</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">10</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4">
<span class="Bold">Constitutional </span><span class="Bold">Symptoms/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>/Ocular/Visual</span>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">11</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Tearing</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">Dysphasia</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">12</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">8</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4"><span class="Bold">Dermatology/Skin</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Rrule" align="center">38</td>
<td class="Rrule" align="center">44</td>
<td class="Rrule" align="center">67</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Pruritis</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry Skin</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4"><span class="Bold">Gastrointestinal</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Mouth Dryness</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4"><span class="Bold">Hematology/<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> normal ANC<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">9</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4"><span class="Bold">Hepatic/Metabolic/Laboratory/Renal</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Elevated Creatinine</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4"><span class="Bold">Neurology</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">11</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">10</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">6</td>
</tr>
</tbody>
</table>
<p>Adverse reactions were similar in men and women and in patients &lt;65 and <span class="Bold">≥</span>65 years, but older patients may have been more susceptible to <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>. The following additional adverse reactions, at least possibly related to treatment and potentially important, were reported in <span class="Bold">≥</span>2% and &lt;5% of the patients in the ELOXATIN and 5-fluorouracil/leucovorin combination arm (listed in decreasing order of frequency): metabolic, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, catheter <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, pulmonary, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail changes</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="76458" conceptname="Rectal pain">rectal pain</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, unknown <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> changes, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline">Previously Treated Patients with Advanced Colorectal Cancer</span></p>
<p>Four hundred and fifty patients (about 150 receiving the combination of ELOXATIN and 5-fluorouracil/leucovorin) were studied in a randomized trial in patients with refractory and relapsed colorectal cancer <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. The adverse reaction profile in this study was similar to that seen in other studies and the adverse reactions in this trial are shown in the tables below. <br>Thirteen percent of patients in the ELOXATIN and 5-fluorouracil/leucovorin combination arm and 18% in the 5-fluorouracil/leucovorin arm of the previously treated study had to discontinue treatment because of adverse effects related to gastrointestinal, or hematologic adverse reactions, or neuropathies. Both 5-fluorouracil and ELOXATIN are associated with gastrointestinal and hematologic adverse reactions. When ELOXATIN is administered in combination with 5-fluorouracil, the incidence of these events is increased.</p>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> within 30 days of treatment in the previously treated study, regardless of causality, was 5% with the ELOXATIN and 5-fluorouracil/leucovorin combination, 8% with ELOXATIN alone, and 7% with 5-fluorouracil/leucovorin. Of the 7 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> that occurred on the ELOXATIN and 5-fluorouracil/leucovorin combination arm within 30 days of stopping treatment, 3 may have been treatment related, associated with <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> or <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. </p>
<p>The following table provides adverse reactions reported in the previously treated study <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>] </span>by body system and in decreasing order of frequency in the ELOXATIN and 5-fluorouracil/leucovorin combination arm for events with overall incidences <span class="Bold">≥</span>5% and for grade 3/4 events with incidences ≥1%. This table does not include hematologic and blood chemistry abnormalities; these are shown separately below.</p>
<table width="100%">
<caption><span>Table 7 – Adverse Reactions Reported In Previously Treated Colorectal Cancer Clinical Trial (≥5% of all patients and with ≥1% NCI Grade 3/4 events)</span></caption>
<col align="left" valign="bottom" width="22%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="2">5-FU/LV<br>(N = 142)</th>
<th class="Botrule Rrule" align="center" colspan="2">ELOXATIN<br>(N = 153)</th>
<th class="Botrule Rrule" align="center" colspan="2">ELOXATIN + 5-FU/LV<br>(N = 150)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Adverse reaction<br>(WHO/Pref)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Any Event</td>
<td class="Rrule" align="center">98</td>
<td class="Rrule" align="center">41</td>
<td class="Rrule" align="center">100</td>
<td class="Rrule" align="center">46</td>
<td class="Rrule" align="center">99</td>
<td class="Rrule" align="center">73</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="7"><span class="Bold">Cardiovascular</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="7"><span class="Bold">Constitutional Symptoms/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">52</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">61</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">68</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="7"><span class="Bold">Dermatology/Skin</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection Site Reaction</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="7"><span class="Bold">Gastrointestinal</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">44</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">46</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">67</td>
<td class="Rrule" align="center">11</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">59</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">64</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">65</td>
<td class="Rrule" align="center">11</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">37</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">40</td>
<td class="Rrule" align="center">9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Rrule" align="center">32</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">37</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">33</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">29</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="7"><span class="Bold">Hematology/<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">29</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile Neutropenia</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="7"><span class="Bold">Hepatic/Metabolic/Laboratory/Renal</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="7"><span class="Bold">Neurology</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">76</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">74</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Acute </td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">65</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">56</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Persistent </td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">43</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">48</td>
<td class="Rrule" align="center">6</td>
</tr>
</tbody>
</table>
<p>The following table provides adverse reactions reported in the previously treated study <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span> by body system and in decreasing order of frequency in the ELOXATIN and 5-fluorouracil/leucovorin combination arm for events with overall incidences ≥5% but with incidences &lt;1% NCI Grade 3/4 events.</p>
<table width="75%">
<caption><span>Table 8 - Adverse Reactions Reported In Previously Treated Colorectal Cancer Clinical Trial (≥5% of all patients but with &lt; 1% NCI Grade 3/4 events)</span></caption>
<col align="left" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center">5-FU/LV<br>(N = 142)</th>
<th class="Botrule Rrule" align="center">ELOXATIN<br> (N = 153)</th>
<th class="Botrule Rrule" align="center">ELOXATIN + 5-FU/LV<br>(N = 150)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Adverse reaction<br>(WHO/Pref)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="4"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span>/Immunology</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">15</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reaction</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">10</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">9</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4"><span class="Bold">Cardiovascular</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span> </td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">10</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4"><span class="Bold">Constitutional Symptoms/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>/Ocular/Visual</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">17</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">10</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Abnormal <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">Lacrimation</span> </td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4"><span class="Bold">Dermatology/Skin</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hand-Foot Syndrome</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">11</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">10</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4"><span class="Bold">Gastrointestinal</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">32</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">14</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Perversion</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">13</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">Mucositis</span> </td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4"><span class="Bold">Hepatic/Metabolic/Laboratory/Renal</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4"><span class="Bold">Neurology</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">13</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">9</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4"><span class="Bold">Pulmonary</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Upper Resp Tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">10</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">9</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">Hiccup</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">5</td>
</tr>
</tbody>
</table>
<p>Adverse reactions were similar in men and women and in patients &lt;65 and ≥65 years, but older patients may have been more susceptible to <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>. The following additional adverse reactions, at least possibly related to treatment and potentially important, were reported in ≥2% and &lt;5% of the patients in the ELOXATIN and 5-fluorouracil/leucovorin combination arm (listed in decreasing order of frequency): <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, abnormal micturition frequency, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4215578" conceptname="Proctitis">proctitis</span>, involuntary muscle contractions, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span>, tenesmus, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, enlarged abdomen, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline">Hematologic Changes</span></p>
<p>The following tables list the hematologic changes occurring in ≥5% of patients, based on laboratory values and NCI grade, with the exception of those events occurring in adjuvant patients and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> in the patients previously untreated for advanced colorectal cancer, respectively, which are based on AE reporting and NCI grade alone.</p>
<table width="75%">
<caption><span>Table 9 - Adverse Hematologic Reactions in Patients with Colon Cancer Receiving Adjuvant Therapy (≥5% of patients)</span></caption>
<col align="left" valign="top" width="28%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="2">ELOXATIN + 5-FU/LV<br>(N=1108)</th>
<th class="Botrule Rrule" align="center" colspan="2">5-FU/LV<br>(N=1111)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Hematology  Parameter</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Rrule" align="center">76</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">67</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Rrule" align="center">79</td>
<td class="Rrule" align="center">41</td>
<td class="Rrule" align="center">40</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Rrule" align="center">77</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
</tbody>
</table>
<table width="75%">
<caption><span>Table 10 – Adverse Hematologic Reactions in Patients Previously Untreated for Advanced Colorectal Cancer (≥5% of patients)</span></caption>
<col align="left" valign="top" width="22%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="2">ELOXATIN + 5-FU/LV<br>N=259</th>
<th class="Botrule Rrule" align="center" colspan="2">Irinotecan+ 5-FU/LV<br>N=256</th>
<th class="Botrule Rrule" align="center" colspan="2">ELOXATIN + irinotecan<br>N=258</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Hematology Parameter</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td class="Rrule" align="center">85</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">84</td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">76</td>
<td class="Rrule" align="center">24</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Rrule" align="center">81</td>
<td class="Rrule" align="center">53</td>
<td class="Rrule" align="center">77</td>
<td class="Rrule" align="center">44</td>
<td class="Rrule" align="center">71</td>
<td class="Rrule" align="center">36</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Rrule" align="center">71</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">44</td>
<td class="Rrule" align="center">4</td>
</tr>
</tbody>
</table>
<table width="75%">
<caption><span>Table 11 – Adverse Hematologic Reactions in Previously Treated Patients (≥5% of patients)</span></caption>
<col align="left" valign="top" width="22%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="13%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="2" valign="top">5-FU/LV<br>(N=142)</th>
<th class="Botrule Rrule" align="center" colspan="2" valign="top">ELOXATIN<br>(N=153)</th>
<th class="Botrule Rrule" align="center" colspan="2">ELOXATIN + 5-FU/LV<br>(N=150)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Hematology Parameter</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Rrule" align="center">68</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">64</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">81</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td class="Rrule" align="center">34</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">76</td>
<td class="Rrule" align="center">19</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">73</td>
<td class="Rrule" align="center">44</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">30</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">64</td>
<td class="Rrule" align="center">4</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.5"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> was frequently reported with the combination of ELOXATIN and infusional 5-fluorouracil/leucovorin. The incidence of all hemorrhagic events in the adjuvant and previously treated patients was higher on the ELOXATIN combination arm compared to the infusional 5-fluorouracil/leucovorin arm. These events included <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, and <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>. In the adjuvant trial, two patients died from <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">intracerebral hemorrhages</span>. </p>
<p>The incidence of Grade 3/4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> was 2% in adjuvant patients with colon cancer. In patients treated for advanced colorectal cancer the incidence of Grade 3/4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> was 3–5%, and the incidence of these events was greater for the combination of ELOXATIN and 5-fluorouracil/leucovorin over the irinotecan plus 5-fluorouracil/leucovorin or 5-fluorouracil/leucovorin control groups. Grade 3/4 <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> was reported in 0.2% of adjuvant patients receiving ELOXATIN and 5-fluorouracil/leucovorin. In the previously untreated patients, the incidence of <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> was 10% in the ELOXATIN and 5-fluorouracil/leucovorin arm, and 2% and 1%, respectively, in the irinotecan plus 5-fluorouracil/leucovorin or irinotecan plus ELOXATIN arms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.6"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> was frequently observed with the combination of ELOXATIN and 5-fluorouracil/leucovorin, with Grade 3 and 4 events reported in 29% and 12% of adjuvant patients with colon cancer, respectively. In the adjuvant trial, 3 patients died from <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>/<span class="product-label-link" type="condition" conceptid="40484176" conceptname="Neutropenic sepsis">neutropenic sepsis</span>. Grade 3 and 4 events were reported in 35% and 18% of the patients previously untreated for advanced colorectal cancer, respectively. Grade 3 and 4 events were reported in 27% and 17% of previously treated patients, respectively. In adjuvant patients the incidence of either <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (0.7%) or documented <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with concomitant grade 3/4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (1.1%) was 1.8% in the ELOXATIN and 5-fluorouracil/leucovorin arm. The incidence of <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> in the patients previously untreated for advanced colorectal cancer was 15% (3% of cycles) in the irinotecan plus 5-fluorouracil/leucovorin arm and 4% (less than 1% of cycles) in the ELOXATIN and 5-fluorouracil/leucovorin combination arm. Additionally, in this same population, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with grade 3 or 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> was 12% in the irinotecan plus 5-fluorouracil/leucovorin, and 8% in the ELOXATIN and 5-fluorouracil/leucovorin combination. The incidence of <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> in the previously treated patients was 1% in the 5-fluorouracil/leucovorin arm and 6% (less than 1% of cycles) in the ELOXATIN and 5-fluorouracil/leucovorin combination arm.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.7"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline">Gastrointestinal</span></p>
<p>In patients receiving the combination of ELOXATIN plus infusional 5-fluorouracil/leucovorin for adjuvant treatment for colon cancer the incidence of Grade 3/4 <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> was greater than those receiving infusional 5-fluorouracil/leucovorin alone (see table). In patients previously untreated for advanced colorectal cancer receiving the combination of ELOXATIN and 5-fluorouracil/leucovorin, the incidence of Grade 3 and 4 <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was less compared to irinotecan plus 5-fluorouracil/leucovorin controls (see table). In previously treated patients receiving the combination of ELOXATIN and 5-fluorouracil/leucovorin, the incidence of Grade 3 and 4 <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>/<span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> increased compared to 5-fluorouracil/leucovorin controls (see table).</p>
<p>The incidence of gastrointestinal adverse reactions in the previously untreated and previously treated patients appears to be similar across cycles. Premedication with antiemetics, including 5-HT<span class="Sub">3</span> blockers, is recommended. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> and <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> may be exacerbated by the addition of ELOXATIN to 5-fluorouracil/leucovorin, and should be managed with appropriate supportive care. Since <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> temperature can exacerbate acute neurological symptoms, ice (<span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> prophylaxis) should be avoided during the infusion of ELOXATIN.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.8"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline">Dermatologic</span></p>
<p>ELOXATIN did not increase the incidence of <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> compared to 5-fluorouracil/leucovorin alone. No complete <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> was reported. The incidence of Grade 3/4 <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorders</span> was 2% in both the ELOXATIN plus infusional 5-fluorouracil/leucovorin and the infusional 5-fluorouracil/leucovorin alone arms in the adjuvant colon cancer patients. The incidence of hand-foot syndrome in patients previously untreated for advanced colorectal cancer was 2% in the irinotecan plus 5-fluorouracil/leucovorin arm and 7% in the ELOXATIN and 5-fluorouracil/leucovorin combination arm. The incidence of hand-foot syndrome in previously treated patients was 13% in the 5-fluorouracil/leucovorin arm and 11% in the ELOXATIN and 5-fluorouracil/leucovorin combination arm.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.9"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline">Intravenous Site Reactions</span></p>
<p><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span>, in some cases including <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, has been reported. <br><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span>, including <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.10"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline">Anticoagulation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></span></p>
<p>There have been reports while on study and from post-marketing surveillance of prolonged <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time and INR occasionally associated with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> in patients who received ELOXATIN plus 5-fluorouracil/leucovorin while on anticoagulants. Patients receiving ELOXATIN plus 5-fluorouracil/leucovorin and requiring oral anticoagulants may require closer monitoring.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.11"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline">Renal</span></p>
<p>About 5–10% of patients in all groups had some degree of elevation of serum creatinine. The incidence of Grade 3/4 elevations in serum creatinine in the ELOXATIN and 5-fluorouracil/leucovorin combination arm was 1% in the previously treated patients. Serum creatinine measurements were not reported in the adjuvant trial.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.12"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline">Hepatic</span></p>
<p>Hepatotoxicity (defined as elevation of liver enzymes) appears to be related to ELOXATIN combination therapy <span class="Italics">[see Warnings and Precautions (5.4)]</span>. The following tables list the clinical chemistry changes associated with hepatic toxicity occurring in ≥5% of patients, based on adverse reactions reported and NCI CTC grade for adjuvant patients and patients previously untreated for advanced colorectal cancer, laboratory values and NCI CTC grade for previously treated patients.</p>
<table width="75%">
<caption><span>Table 12 - Adverse Hepatic Reactions in Patients with Stage II or III Colon Cancer Receiving Adjuvant Therapy (≥5% of patients)</span></caption>
<col align="left" valign="top" width="28%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="2">ELOXATIN + 5-FU/LV<br>(N=1108)</th>
<th class="Botrule Rrule" align="center" colspan="2">5-FU/LV<br>(N=1111)</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="center" valign="middle">Hepatic Parameter</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Increase in transaminases</td>
<td class="Rrule" align="center">57</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">34</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">ALP increased</td>
<td class="Rrule" align="center">42</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">&lt;1</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Bilirubinaemia</span></td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">5</td>
</tr>
</tbody>
</table>
<table width="75%">
<caption><span>Table 13 – Adverse Hepatic – Clinical Chemistry Abnormalities in Patients Previously Untreated for Advanced Colorectal Cancer (≥5% of patients)</span></caption>
<col align="left" valign="top" width="22%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="2">ELOXATIN + 5-FU/LV<br>N=259</th>
<th class="Botrule Rrule" align="center" colspan="2">irinotecan + 5-FU/LV<br>N=256</th>
<th class="Botrule Rrule" align="center" colspan="2">ELOXATIN + irinotecan<br>N=258</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center" valign="top">Clinical Chemistry</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">ALT<br>(SGPT-ALAT)</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">AST<br>(<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>-ASAT)</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Alkaline Phosphatase</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Total Bilirubin</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
</tr>
</tbody>
</table>
<table width="75%">
<caption><span>Table 14 – Adverse Hepatic – Clinical Chemistry Abnormalities in Previously Treated Patients (≥5% of patients)</span></caption>
<col align="left" valign="top" width="22%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="2">5-FU/LV<br>(N=142)</th>
<th class="Botrule Rrule" align="center" colspan="2">ELOXATIN<br>(N=153)</th>
<th class="Botrule Rrule" align="center" colspan="2">ELOXATIN + 5-FU/LV<br>(N=150)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center" valign="top">Clinical Chemistry</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
<th class="Rrule" align="center">All Grades<br>(%)</th>
<th class="Rrule" align="center">Grade 3/4<br>(%)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">ALT<br>(SGPT-ALAT)</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">36</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">AST<br>(<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>-ASAT)</td>
<td class="Rrule" align="center">39</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">54</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">47</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Total Bilirubin</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">1</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.13"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span></span></p>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> in adjuvant patients with colon cancer was 6% (1.8% grade 3/4) in the infusional 5-fluorouracil/leucovorin arm and 6% (1.2% grade 3/4) in the ELOXATIN and infusional 5-fluorouracil/leucovorin combined arm, respectively. The incidence was 6 and 9% of the patients previously untreated for advanced colorectal cancer and previously treated patients in the ELOXATIN and 5-fluorouracil/leucovorin combination arm, respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of ELOXATIN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics Underline">Body as a whole: </span><br><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> </p>
<p><span class="Italics Underline">Central and peripheral <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">nervous system disorders</span>:</span><br>loss of deep tendon reflexes, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, Lhermitte's sign, cranial nerve palsies, <span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">fasciculations</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible Posterior Leukoencephalopathy Syndrome</span> (RPLS, also known as PRES).			</p>
<p><span class="Italics Underline">Hearing and vestibular system disorders:</span><br><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span> 						</p>
<p><span class="Italics Underline">Infusion reactions/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>:</span><br> <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span></p>
<p><span class="Italics Underline">Liver and Gastrointestinal system disorders:</span><br> severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> resulting in <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (including <span class="Italics">Clostridium difficile</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>), <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>; <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>; <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>; veno-occlusive disease of liver also known as <span class="product-label-link" type="condition" conceptid="4277276" conceptname="Veno-occlusive disease of the liver">sinusoidal obstruction syndrome</span>, and perisinusoidal <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> which rarely may progress.</p>
<p><span class="Italics Underline">Platelet, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">clotting disorders</span>:</span><br>immuno-allergic <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> <br>prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time and of INR in patients receiving anticoagulants						</p>
<p><span class="Italics Underline">Red Blood Cell disorders:</span><br><span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">hemolytic uremic syndrome</span>, immuno-allergic <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>	</p>
<p><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal disorders</span>:</span><br><span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">Acute tubular necrosis</span>, <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">acute interstitial nephritis</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. 	</p>
<p><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory system disorders</span>:</span><br><span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>, and other <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung diseases</span> (sometimes fatal)</p>
<p><span class="Italics Underline">Vision disorders:</span><br>decrease of visual acuity, visual field disturbance, <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span> and transient <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span> (reversible following therapy discontinuation)</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No specific cytochrome P-450-based drug interaction studies have been conducted. No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between 85 mg/m<span class="Sup">2</span> ELOXATIN and 5-fluorouracil/leucovorin has been observed in patients treated every 2 weeks. Increases of 5-fluorouracil plasma concentrations by approximately 20% have been observed with doses of 130 mg/m<span class="Sup">2</span> ELOXATIN dosed every 3 weeks. Because platinum-containing species are eliminated primarily through the kidney, clearance of these products may be decreased by coadministration of potentially nephrotoxic compounds; although, this has not been specifically studied <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8.1.1"></a><p></p>
<h3></h3>
<p class="First">Pregnancy Category D </p>
<p>Based on direct interaction with DNA, ELOXATIN may cause fetal harm when administered to a pregnant woman.  There are no adequate and well-controlled studies of ELOXATIN in pregnant women.  Reproductive toxicity studies in rats demonstrated adverse effects on fertility and embryo-fetal development at maternal doses that were below the recommended human dose based on body surface area.  If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.  Women of childbearing potential should be advised to avoid becoming pregnant and use effective contraception while receiving treatment with ELOXATIN.  </p>
<p>Pregnant rats were administered oxaliplatin at less than one-tenth the recommended human dose based on body surface area during gestation days 1–5 (pre-implantation), 6–10, or 11–16 (during organogenesis).  Oxaliplatin caused developmental mortality (increased early resorptions) when administered on days 6–10 and 11–16 and adversely affected fetal growth (decreased fetal weight, delayed ossification) when administered on days 6–10.  Administration of oxaliplatin to male and female rats prior to mating resulted in 97% post-implantation loss in animals that received approximately one-seventh the recommended human dose based on the body surface area.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether ELOXATIN or its derivatives are excreted in human milk.  Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from ELOXATIN, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The effectiveness of oxaliplatin in children has not been established.  Oxaliplatin has been tested in 2 Phase 1 and 2 Phase 2 trials in 235 patients ages 7 months to 22 years with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> (see below) and no significant activity observed.</p>
<p>In a Phase 1/2 study, oxaliplatin was administered as a 2-hour intravenous infusion on Days 1, 8 and 15 every 4 weeks (1 cycle), for a maximum of 6 cycles, to 43 patients with refractory or relapsed malignant <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>, mainly <span class="product-label-link" type="condition" conceptid="4333766" conceptname="Neuroblastoma">neuroblastoma</span> and <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteosarcoma</span>. Twenty eight pediatric patients in the Phase 1 study received oxaliplatin at 6 dose levels starting at 40 mg/m<span class="Sup">2</span> with escalation to 110 mg/m<span class="Sup">2</span>. The dose limiting toxicity (DLT) was <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">sensory neuropathy</span> at the 110 mg/m<span class="Sup">2</span> dose.  Fifteen patients received oxaliplatin at a dose of 90 mg/m<span class="Sup">2</span> intravenous  in the Phase 2 portion of the study.  At this dose, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> (60%, G3/4: 7%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (40%, G3/4: 7%) and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (40%, G3/4: 27%) were the main adverse reactions.   No responses were observed.</p>
<p>In a second Phase 1 study, oxaliplatin was administered to 26 pediatric patients as a 2-hour intravenous  infusion on day 1 every 3 weeks (1 cycle) at 5 dose levels starting at 100 mg/m<span class="Sup">2</span> with escalation to 160 mg/m<span class="Sup">2</span>, for a maximum of 6 cycles.  In a separate cohort, oxaliplatin 85 mg/m<span class="Sup">2</span> was administered on day 1 every 2 weeks, for a maximum of 9 doses. Patients had metastatic or unresectable <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> mainly <span class="product-label-link" type="condition" conceptid="4333766" conceptname="Neuroblastoma">neuroblastoma</span> and ganglioneuroblastoma. No responses were observed.  The DLT was <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">sensory neuropathy</span> at the 160 mg/m<span class="Sup">2</span> dose.  Based on these studies, oxaliplatin 130 mg/m<span class="Sup">2</span> as a 2-hour intravenous  infusion on day 1 every 3 weeks (1 cycle) was used in subsequent Phase II studies. A dose of 85 mg/m<span class="Sup">2</span> on day 1 every 2 weeks was also found to be tolerable.</p>
<p>In one Phase 2 study, 43 pediatric patients with recurrent or refractory embryonal CNS tumors received oxaliplatin 130 mg/m<span class="Sup">2</span> every 3 weeks for a maximum of 12 months in absence of progressive disease or unacceptable toxicity. In patients &lt; 10 kg the oxaliplatin dose used was 4.3 mg/kg. The most common adverse reactions reported were <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (67%, G3/4: 12%), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (65%, G3/4: 5%), <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (65%, G3/4: 26%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (65%, G3/4: 7%), <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (58%, G3/4: 16%) and <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">sensory neuropathy</span> (40%, G3/4: 5%). One partial response was observed.</p>
<p>In a second Phase 2 study, 123 pediatric patients with recurrent <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>, including <span class="product-label-link" type="condition" conceptid="4333766" conceptname="Neuroblastoma">neuroblastoma</span>, <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteosarcoma</span>,  Ewing <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> or peripheral PNET, <span class="product-label-link" type="condition" conceptid="4239952" conceptname="Ependymoma">ependymoma</span>, <span class="product-label-link" type="condition" conceptid="4116201" conceptname="Rhabdomyosarcoma">rhabdomyosarcoma</span>, <span class="product-label-link" type="condition" conceptid="4001172" conceptname="Hepatoblastoma">hepatoblastoma</span>, high grade <span class="product-label-link" type="condition" conceptid="4298902" conceptname="Astrocytoma">astrocytoma</span>, Brain stem <span class="product-label-link" type="condition" conceptid="4019491" conceptname="Glioma">glioma</span>, low grade <span class="product-label-link" type="condition" conceptid="4298902" conceptname="Astrocytoma">astrocytoma</span>, malignant germ cell tumor and other tumors of interest received oxaliplatin 130 mg/m<span class="Sup">2</span> every 3 weeks for a maximum of 12 months or 17 cycles. In patients ≤ 12 months old the oxaliplatin dose used was 4.3 mg/kg. The most common adverse reactions reported were <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">sensory neuropathy</span> (52%, G3/4: 12%), <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (37%, G3/4: 17%), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (37%, G3/4: 9%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (26%, G3/4:4%), ALT increased (24%, G3/4: 6%), AST increased (24%, G3/4: 2%), and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (23%, G3/:4 3%). Two partial responses were observed.</p>
<p>The pharmacokinetic parameters of ultrafiltrable platinum have been evaluated in 105 pediatric patients during the first cycle. The mean clearance in pediatric patients estimated by the population pharmacokinetic analysis was 4.7 L/h. The inter-patient variability of platinum clearance in pediatric cancer patients was 41%. Mean platinum pharmacokinetic parameters in ultrafiltrate were C<span class="Sub">max</span> of 0.75 ± 0.24 mcg/mL, AUC<span class="Sub">0–48</span> of 7.52 ± 5.07 mcg∙h/mL and AUC<span class="Sub">inf</span> of 8.83 ± 1.57 mcg∙h/mL at 85 mg/m<span class="Sup">2</span> of oxaliplatin and C<span class="Sub">max</span> of 1.10 ± 0.43 mcg/mL, AUC<span class="Sub">0–48</span> of 9.74 ± 2.52 mcg∙h/mL and AUC<span class="Sub">inf</span> of 17.3 ± 5.34 mcg∙h/mL at 130 mg/m<span class="Sup">2</span> of oxaliplatin.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">No significant effect of age on the clearance of ultrafilterable platinum has been observed. <br></p>
<p>In the adjuvant therapy colon cancer randomized clinical trial, <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>] </span>723 patients treated with ELOXATIN and infusional 5-fluorouracil/leucovorin were &lt;65 years and 400 patients were ≥65 years. </p>
<p>A descriptive subgroup analysis demonstrated that the improvement in DFS for the ELOXATIN combination arm compared to the infusional 5-fluorouracil/leucovorin alone arm appeared to be maintained across genders.  The effect of ELOXATIN in patients ≥65 years of age was not conclusive.  Insufficient subgroup sizes prevented analysis by race.</p>
<p>Patients ≥ 65 years of age receiving the ELOXATIN combination therapy experienced more grade 3–4 <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> than patients &lt; 65 years of age (45% versus 39%).</p>
<p>In the previously untreated for advanced colorectal cancer randomized clinical trial <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span> of ELOXATIN, 160 patients treated with ELOXATIN and 5-fluorouracil/leucovorin were &lt; 65 years and 99 patients were ≥65 years. The same efficacy improvements in response rate, time to <span class="product-label-link" type="condition" conceptid="4168352" conceptname="Tumor progression">tumor progression</span>, and overall survival were observed in the ≥65 year old patients as in the overall study population. In the previously treated for advanced colorectal cancer randomized clinical trial <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>] </span>of ELOXATIN, 95 patients treated with ELOXATIN and 5-fluorouracil/leucovorin were &lt;65 years and 55 patients were ≥65 years. The rates of overall adverse reactions, including grade 3 and 4 events, were similar across and within arms in the different age groups in all studies. The incidence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> were higher in patients ≥65 years old. No adjustment to starting dose was required in patients ≥65 years old.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The exposure (AUC) of unbound platinum in plasma ultrafiltrate tends to increase in renally impaired patients<span class="Italics"> [see<a href="#S12.3"> Pharmacokinetics (12.3)</a>]</span>. Caution and close monitoring should be exercised when ELOXATIN is administered to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The starting ELOXATIN dose does not need to be reduced in patients with mild (creatinine clearance=50-80 mL/min) or moderate (creatinine clearance=30-49 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. However, the starting dose of ELOXATIN should be reduced in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt; 30 mL/min)<span class="Italics"> [see<a href="#S2.2"> Dosage and Administration (2.2)</a>]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2></h2>
<p class="First">There is no known antidote for ELOXATIN <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. In addition to <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, the anticipated complications of an ELOXATIN <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> include <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>. </p>
<p>Several cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> have been reported with ELOXATIN. Adverse reactions observed were Grade 4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (&lt;25,000/mm<span class="Sup">3</span>) without any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">sensory neuropathy</span> such as <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> and facial <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdomen enlarged</span> and Grade 4 <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, Grade 4 <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>,  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. 								</p>
<p>Patients suspected of receiving an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should be monitored, and supportive treatment should be administered. The maximum dose of oxaliplatin that has been administered in a single infusion is 825 mg.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">ELOXATIN<span class="Sup">®</span> (oxaliplatin injection) is an antineoplastic agent with the molecular formula C<span class="Sub">8</span>H<span class="Sub">14</span>N<span class="Sub">2</span>O<span class="Sub">4</span>Pt and the chemical name of <span class="Italics">cis</span>-[(1 <span class="Italics">R</span>,2 <span class="Italics">R</span>)-1,2-cyclohexanediamine-<span class="Italics">N</span>,<span class="Italics">N</span>'] [oxalato(2-)- <span class="Italics">O</span>,<span class="Italics">O</span>'] platinum. Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane(DACH) and with an oxalate ligand as a leaving group.</p>
<div class="Figure"><img alt="chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3c740b43-f396-4998-bc66-6964a21f7161&amp;name=eloxatin-02.jpg"></div>
<p>The molecular weight is 397.3. Oxaliplatin is slightly soluble in water at 6 mg/mL, very slightly soluble in methanol, and practically insoluble in ethanol and acetone. <br><br></p>
<p>ELOXATIN is supplied in vials containing 50 mg or 100 mg of oxaliplatin as a sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL.  Water for Injection, USP is present as an inactive ingredient.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the <span class="Italics">N7 </span>positions of two adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by an intervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.</p>
<p><span class="Italics">In vivo</span> studies have shown antitumor activity of oxaliplatin against colon carcinoma. In combination with 5-fluorouracil, oxaliplatin exhibits <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> antiproliferative activity greater than either compound alone in several tumor models [HT29 (colon), GR (mammary), and L1210 (<span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>)].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The reactive oxaliplatin derivatives are present as a fraction of the unbound platinum in plasma ultrafiltrate. The decline of ultrafilterable platinum levels following oxaliplatin administration is triphasic, characterized by two relatively short distribution phases (t<span class="Sub">1/2α</span>; 0.43 hours and t<span class="Sub">1/2β</span>; 16.8 hours) and a long terminal elimination phase (t<span class="Sub">1/2γ</span>; 391 hours). Pharmacokinetic parameters obtained after a single 2-hour intravenous infusion of ELOXATIN at a dose of 85 mg/m<span class="Sup">2</span> expressed as ultrafilterable platinum were C<span class="Sub">max</span> of 0.814 mcg/mL and volume of distribution of 440 L. <br>Interpatient and intrapatient variability in ultrafilterable platinum exposure (AUC<span class="Sub">0–48hr</span>) assessed over 3 cycles was moderate to low (23% and 6%, respectively). A pharmacodynamic relationship between platinum ultrafiltrate levels and clinical safety and effectiveness has not been established.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline">Distribution</span></p>
<p>At the end of a 2-hour infusion of ELOXATIN, approximately 15% of the administered platinum is present in the systemic circulation. The remaining 85% is rapidly distributed into tissues or eliminated in the urine. In patients, plasma protein binding of platinum is irreversible and is greater than 90%. The main binding proteins are albumin and gamma-globulins. Platinum also binds irreversibly and accumulates (approximately 2-fold) in erythrocytes, where it appears to have no relevant activity. No platinum accumulation was observed in plasma ultrafiltrate following 85 mg/m<span class="Sup">2</span> every two weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline">Metabolism</span></p>
<p>Oxaliplatin undergoes rapid and extensive nonenzymatic biotransformation. There is no evidence of cytochrome P450-mediated metabolism <span class="Italics">in vitro</span>.</p>
<p>Up to 17 platinum-containing derivatives have been observed in plasma ultrafiltrate samples from patients, including several cytotoxic species (monochloro DACH platinum, dichloro DACH platinum, and monoaquo and diaquo DACH platinum) and a number of noncytotoxic, conjugated species.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.3"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline">Elimination</span></p>
<p>The major route of platinum elimination is renal excretion. At five days after a single 2-hour infusion of ELOXATIN, urinary elimination accounted for about 54% of the platinum eliminated, with fecal excretion accounting for only about 2%. Platinum was cleared from plasma at a rate (10 – 17 L/h) that was similar to or exceeded the average human glomerular filtration rate (GFR; 7.5 L/h). There was no significant effect of gender on the clearance of ultrafilterable platinum. The renal clearance of ultrafilterable platinum is significantly correlated with GFR.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.4"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics Underline">Pharmacokinetics in Special Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.4.1"></a><p></p>
<h4></h4>
<p class="First"><span class="Underline">Pediatric</span></p>
<p><span class="Italics">[See <a href="#S8.4">Use In Specific Patient Populations (8.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.4.2"></a><p></p>
<h4></h4>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>A study was conducted in 38 patients with advanced GI cancer and varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Patients in the normal (creatinine clearance (CrCL) &gt; 80 mL/min, N=11), mild (CrCL=50-80 mL/min, N=13), and moderate (CrCL=30-49 mL/min, N=10) groups were treated with 85 mg/m<span class="Sup">2</span> ELOXATIN and those in the severe (CrCL &lt; 30 mL/min, N=4) group were treated with 65 mg/m<span class="Sup">2</span> ELOXATIN. The mean AUC of unbound platinum was 40%, 95%, and 342% higher in the mild, moderate, and severe groups, respectively, than in the normal group. Mean C<span class="Sub">max</span> of unbound platinum appeared to be similar among the normal, mild and moderate renal function groups, but was 38% higher in the severe group than in the normal group. Caution should be exercised in renally impaired patients<span class="Italics"> [see<a href="#S8.6"> Use in Specific Populations (8.6)</a>]</span>. The starting dose of ELOXATIN should be reduced in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span><span class="Italics"> [see<a href="#S2.2"> Dosage and Administration (2.2)</a>]</span>. The starting dose of ELOXATIN should be reduced in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span><span class="Italics"> [see<a href="#S2.2"> Dosage and Administration (2.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.4.3"></a><p></p>
<h4></h4>
<p class="First"><span class="Underline">Drug - Drug Interactions</span></p>
<p>No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between 85 mg/m<span class="Sup">2</span> of ELOXATIN and infusional 5-fluorouracil has been observed in patients treated every 2 weeks, but increases of 5-fluorouracil plasma concentrations by approximately 20% have been observed with doses of 130 mg/m<span class="Sup">2</span> of ELOXATIN administered every 3 weeks. <span class="Italics">In vitro</span>, platinum was not displaced from plasma proteins by the following medications: erythromycin, salicylate, sodium valproate, granisetron, and paclitaxel. <span class="Italics">In vitro</span>, oxaliplatin is not metabolized by, nor does it inhibit, human cytochrome P450 isoenzymes. No P450-mediated drug-drug interactions are therefore anticipated in patients. <br>Since platinum-containing species are eliminated primarily through the kidney, clearance of these products may be decreased by co-administration of potentially nephrotoxic compounds, although this has not been specifically studied.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term animal studies have not been performed to evaluate the carcinogenic potential of oxaliplatin. Oxaliplatin was not mutagenic to bacteria (Ames test) but was mutagenic to mammalian cells <span class="Italics">in vitro</span> (L5178Y mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay). Oxaliplatin was clastogenic both <span class="Italics">in vitro</span> (chromosome aberration in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>) and <span class="Italics">in vivo</span> (mouse bone marrow micronucleus assay).</p>
<p>In a fertility study, male rats were given oxaliplatin at 0, 0.5, 1, or 2 mg/kg/day for five days every 21 days for a total of three cycles prior to mating with females that received two cycles of oxaliplatin on the same schedule. A dose of 2 mg/kg/day (less than one-seventh the recommended human dose on a body surface area basis) did not affect pregnancy rate, but caused developmental mortality (increased early resorptions, decreased live fetuses, decreased live births) and delayed growth (decreased fetal weight).</p>
<p>Testicular damage, characterized by degeneration, hypoplasia, and <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, was observed in dogs administered oxaliplatin at 0.75 mg/kg/day × 5 days every 28 days for three cycles. A no effect level was not identified. This daily dose is approximately one-sixth of the recommended human dose on a body surface area basis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Combination Adjuvant Therapy with ELOXATIN and Infusional 5-fluorouracil/leucovorin in Patients with Colon Cancer</h2>
<p class="First">An international, multicenter, randomized study compared the efficacy and evaluated the safety of ELOXATIN in combination with an infusional schedule of 5-fluorouracil/leucovorin to infusional 5-fluorouracil/leucovorin alone, in patients with stage II (Dukes' B2) or III (Dukes' C) colon cancer who had undergone complete resection of the primary tumor. The primary objective of the study was to compare the 3-year disease-free survival (DFS) in patients receiving ELOXATIN and infusional 5-fluorouracil/leucovorin to those receiving 5-fluorouracil/leucovorin alone. Patients were to be treated for a total of 6 months (i.e., 12 cycles). A total of 2246 patients were randomized; 1123 patients per study arm. Patients in the study had to be between 18 and 75 years of age, have histologically proven stage II (T<span class="Sub">3</span>–T<span class="Sub">4</span> N0 M0; Dukes' B2) or III (any T N<span class="Sub">1–2 </span>M0; Dukes' C) colon carcinoma (with the inferior pole of the tumor above the peritoneal reflection, i.e., ≥15 cm from the anal margin) and undergone (within 7 weeks prior to randomization) complete resection of the primary tumor without gross or microscopic evidence of residual disease. Patients had to have had no prior chemotherapy, immunotherapy or radiotherapy, and have an ECOG performance status of 0,1, or 2 (KPS ≥ 60%), absolute neutrophil count (ANC) &gt; 1.5x10<span class="Sup">9</span>/L, platelets ≥100×10<span class="Sup">9</span>/L, serum creatinine ≤ 1.25 × ULN total bilirubin &lt; 2 × ULN, AST/ALT &lt; 2 × ULN and carcino-embyrogenic antigen (CEA) &lt; 10 ng/mL. Patients with preexisting <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> (NCI grade ≥ 1) were ineligible for this trial.</p>
<p>The following table shows the dosing regimens for the two arms of the study.</p>
<table width="75%">
<caption><span>Table 15 - Dosing Regimens in Adjuvant Therapy Study</span></caption>
<col align="center" valign="top" width="30%">
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center">Treatment</th>
<th class="Rrule" align="left"></th>
<th class="Rrule" align="center"></th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="center">Arm</th>
<th class="Rrule" align="center">Dose</th>
<th class="Rrule" align="center">Regimen</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="center">
<br>ELOXATIN + 5-FU/LV<br>(FOLFOX4)<br>(N =1123)</td>
<td class="Rrule" align="left">Day 1: ELOXATIN: 85 mg/m<span class="Sup">2</span> (2-hour infusion) + LV: 200 mg/m<span class="Sup">2 </span> (2-hour infusion), followed by<br>5-FU: 400 mg/m<span class="Sup">2</span> (bolus), 600 mg/m<span class="Sup">2</span> (22-hour infusion)<br><br>Day 2: LV: 200 mg/m<span class="Sup">2 </span> (2-hour infusion), followed by 5-FU: 400 mg/m<span class="Sup">2</span> (bolus), 600 mg/m<span class="Sup">2</span> (22-hour infusion)</td>
<td class="Rrule" align="center">every 2 weeks 12 cycles</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="center">
<br> 5-FU/LV<br> (N=1123)</td>
<td class="Rrule Toprule" align="left">Day 1: LV: 200 mg/m<span class="Sup">2 </span> (2-hour infusion), followed by <br> 5-FU: 400 mg/m<span class="Sup">2</span> (bolus), 600 mg/m<span class="Sup">2</span> (22-hour infusion) <br><br> Day 2: LV: 200 mg/m<span class="Sup">2 </span> (2-hour infusion), followed by <br> 5-FU: 400 mg/m<span class="Sup">2</span> (bolus), 600 mg/m<span class="Sup">2</span> (22-hour infusion)</td>
<td class="Rrule Toprule" align="center">every 2 weeks 12 cycles</td>
</tr>
</tbody>
</table>
<p>The following tables show the baseline characteristics and dosing of the patient population entered into this study. The baseline characteristics were well balanced between arms.</p>
<table width="75%">
<caption><span>Table 16 - Patient Characteristics in Adjuvant Therapy Study</span></caption>
<col align="center" valign="bottom" width="50%">
<col align="center" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center">ELOXATIN + infusional<br>5-FU/LV<br>N=1123</th>
<th class="Rrule" align="center">Infusional<br> 5-FU/LV<br>N=1123</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">Sex: Male (%)</td>
<td class="Rrule" align="center">56.1</td>
<td class="Rrule" align="center">52.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Female (%)</td>
<td class="Rrule" align="center">43.9</td>
<td class="Rrule" align="center">47.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Median age (years)</td>
<td class="Rrule" align="center">61.0</td>
<td class="Rrule" align="center">60.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">&lt;65 years of age (%)</td>
<td class="Rrule" align="center">64.4</td>
<td class="Rrule" align="center">66.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">≥65 years of age (%)</td>
<td class="Rrule" align="center">35.6</td>
<td class="Rrule" align="center">33.8</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="3">Karnofsky Performance Status (KPS) (%)</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">100</td>
<td class="Rrule" align="center">29.7</td>
<td class="Rrule" align="center">30.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">90</td>
<td class="Rrule" align="center">52.2</td>
<td class="Rrule" align="center">53.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">80</td>
<td class="Rrule" align="center">4.4</td>
<td class="Rrule" align="center">3.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">70</td>
<td class="Rrule" align="center">13.2</td>
<td class="Rrule" align="center">11.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">≤60</td>
<td class="Rrule" align="center">0.6</td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="3">Primary site (%)</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Colon including cecum</td>
<td class="Rrule" align="center">54.6</td>
<td class="Rrule" align="center">54.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Sigmoid</td>
<td class="Rrule" align="center">31.9</td>
<td class="Rrule" align="center">33.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Recto sigmoid</td>
<td class="Rrule" align="center">12.9</td>
<td class="Rrule" align="center">10.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Other including rectum</td>
<td class="Rrule" align="center">0.6</td>
<td class="Rrule" align="center">0.9</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="3"><span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Bowel obstruction</span> (%)</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Yes</td>
<td class="Rrule" align="center">17.9</td>
<td class="Rrule" align="center">19.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">Perforation (%)</td>
<td align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">Yes</td>
<td class="Lrule" align="center">6.9</td>
<td class="Lrule Rrule" align="center">6.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">Stage at Randomization (%)</td>
<td align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">II (T=3,4 N=0, M=0)</td>
<td class="Rrule" align="center">40.1</td>
<td class="Rrule" align="center">39.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">III (T=any, N=1,2, M=0)</td>
<td class="Rrule" align="center">59.6</td>
<td class="Rrule" align="center">59.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">IV (T=any, N=any, M=1)</td>
<td class="Rrule" align="center">0.4</td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="3">Staging – T (%)</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">T1</td>
<td class="Rrule" align="center">0.5</td>
<td class="Rrule" align="center">0.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">T2</td>
<td class="Rrule" align="center">4.5</td>
<td class="Rrule" align="center">4.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">T3</td>
<td class="Rrule" align="center">76.0</td>
<td class="Rrule" align="center">75.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">T4</td>
<td class="Rrule" align="center">19.0</td>
<td class="Rrule" align="center">18.5</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="3">Staging – N (%)</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">N0</td>
<td class="Rrule" align="center">40.2</td>
<td class="Rrule" align="center">39.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">N1</td>
<td class="Rrule" align="center">39.4</td>
<td class="Rrule" align="center">39.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">N2</td>
<td class="Rrule" align="center">20.4</td>
<td class="Rrule" align="center">20.7</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="3">Staging – M (%)</td></tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">M1</td>
<td class="Rrule" align="center">0.4</td>
<td class="Rrule" align="center">0.8</td>
</tr>
</tbody>
</table>
<table width="75%">
<caption><span>Table 17 - Dosing in Adjuvant Therapy Study</span></caption>
<col align="left" valign="bottom" width="50%">
<col align="center" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">ELOXATIN + infusional<br>5-FU/LV<br>N=1108</th>
<th class="Rrule" align="center">Infusional<br>5-FU/LV<br>N=1111</th>
</tr></thead>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="3">Median Relative Dose Intensity (%)</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  5-FU</td>
<td class="Rrule" align="center">84.4</td>
<td class="Rrule" align="center">97.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  ELOXATIN</td>
<td class="Rrule" align="center">80.5</td>
<td class="Rrule" align="center">N/A</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Median Number of Cycles</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">12</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Median Number of cycles with ELOXATIN</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">N/A</td>
</tr>
</tbody>
</table>
<p>The following table and figures summarize the disease-free survival (DFS) results in the overall randomized population and in patients with stage II and III disease based on an ITT analysis. The median duration of follow-up was approximately 77 months.</p>
<table width="75%">
<caption><span>Table 18 - Summary of DFS analysis – ITT analysis <a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a></span></caption>
<col align="center" valign="bottom" width="40%">
<col align="center" valign="bottom" width="30%">
<col align="center" valign="bottom" width="30%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center">ELOXATIN + Infusional 5-FU/LV</th>
<th class="Rrule" align="center">Infusional<br>5-FU/LV</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center"></th>
<th class="Rrule" align="center"></th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Data cut off for disease free survival 1 June 2006 </dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>Disease-free survival at 5 years</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">‡</a></dt>
<dd>A hazard ratio of less than 1.00 favors Eloxatin + Infusional 5-fluorouracil/leucovorin</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">Parameter</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="3">Overall</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">N</td>
<td class="Rrule" align="center">1123</td>
<td class="Rrule" align="center">1123</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Number of events – relapse or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (%)</td>
<td class="Rrule" align="center" valign="middle">304 (27.1)</td>
<td class="Rrule" align="center" valign="middle">360 (32.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Disease-free survival % [95% CI]<a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a>
</td>
<td class="Rrule" align="center" valign="middle">73.3 [70.7, 76.0]</td>
<td class="Rrule" align="center" valign="middle">67.4 [64.6, 70.2]</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Hazard ratio [95% CI]<a name="footnote-reference-7" href="#footnote-7" class="Sup">‡</a>
</td>
<td class="Rrule" align="center" colspan="2">0.80 [0.68, 0.93]</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Stratified Logrank test</td>
<td class="Rrule" align="center" colspan="2">p=0.003</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="3">Stage III (Dukes' C)</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">N</td>
<td class="Rrule" align="center">672</td>
<td class="Rrule" align="center">675</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Number of events –relapse or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (%)</td>
<td class="Rrule" align="center" valign="middle">226 (33.6)</td>
<td class="Rrule" align="center" valign="middle">271 (40.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Disease-free survival % [95% CI]<a href="#footnote-6" class="Sup">†</a>
</td>
<td class="Rrule" align="center" valign="middle">66.4 [62.7, 70.0]</td>
<td class="Rrule" align="center" valign="middle">58.9 [55.2, 62.7]</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Hazard ratio [95% CI]<a href="#footnote-7" class="Sup">‡</a>
</td>
<td class="Rrule" align="center" colspan="2">0.78 [0.65, 0.93]</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Logrank test</td>
<td class="Rrule" align="center" colspan="2">p=0.005</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="3">Stage II (Dukes' B2)</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">N</td>
<td class="Rrule" align="center">451</td>
<td class="Rrule" align="center">448</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Number of events – relapse or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>  (%)</td>
<td class="Rrule" align="center" valign="middle">78 (17.3)</td>
<td class="Rrule" align="center" valign="middle">89 (19.9)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Disease-free survival % [95% CI] <a href="#footnote-6" class="Sup">†</a>
</td>
<td class="Rrule" align="center" valign="middle">83.7 [80.2, 87.1]</td>
<td class="Rrule" align="center" valign="middle">79.9 [76.2, 83.7]</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hazard ratio [95% CI]<a href="#footnote-7" class="Sup">‡</a>
</td>
<td class="Rrule" align="center" colspan="2">0.84 [0.62, 1.14]</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Logrank test</td>
<td class="Rrule" align="center" colspan="2">p=0.258</td>
</tr>
</tbody>
</table>
<p>In the overall and stage III colon cancer populations DFS was statistically significantly improved in the ELOXATIN combination arm compared to infusional 5-fluorouracil/leucovorin alone. However, a statistically significant improvement in DFS was not noted in Stage II patients.</p>
<p>Figure 2 shows the DFS Kaplan-Meier curves for the comparison of ELOXATIN and infusional 5-fluorouracil/leucovorin combination and infusional 5-fluorouracil/leucovorin alone for the overall population (ITT analysis). </p>
<p>Figure 3 shows the DFS Kaplan-Meier curves for the comparison of ELOXATIN and infusional 5-fluorouracil/leucovorin combination and infusional 5-fluorouracil/leucovorin alone in Stage III patients.</p>
<div class="Figure">
<img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3c740b43-f396-4998-bc66-6964a21f7161&amp;name=eloxatin-03.jpg"><p class="MultiMediaCaption">Figure 2 - DFS Kaplan-Meier curves by treatment arm (cutoff: 1 June 2006) – ITT population</p>
</div>
<div class="Figure">
<img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3c740b43-f396-4998-bc66-6964a21f7161&amp;name=eloxatin-04.jpg"><p class="MultiMediaCaption">Figure 3 - DFS Kaplan-Meier curves by treatment arm in Stage III patients (cutoff: 1 June 2006) – ITT population</p>
</div>
<p>The following table summarizes the overall survival (OS) results in the overall randomized population and in patients with stage II and III disease, based on the ITT analysis.</p>
<br><table width="75%">
<caption><span>Table 19 - Summary of OS analysis - ITT analysis<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a></span></caption>
<colgroup>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="35%">
</colgroup>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Data cut off for overall survival 16 January 2007</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">†</a></dt>
<dd>A hazard ratio of less than 1.00 favors Eloxatin + Infusional 5-fluorouracil/leucovorin</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">Parameter</td>
<td class="Rrule" align="center">Eloxatin + Infusional 5-FU/LV</td>
<td class="Rrule" align="center">Infusional 5-FU/LV</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="3">Overall</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">N</td>
<td class="Rrule" align="center">1123</td>
<td class="Rrule" align="center">1123</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> events (%)</td>
<td class="Rrule" align="center">245 (21.8)</td>
<td class="Rrule" align="center">283 (25.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hazard ratio<a name="footnote-reference-9" href="#footnote-9" class="Sup">†</a>[95% CI]</td>
<td class="Rrule" align="center" colspan="2">0.84 [0.71 , 1.00]</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="3">Stage III (Dukes' C)</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">N</td>
<td class="Rrule" align="center">672</td>
<td class="Rrule" align="center">675</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> events (%)</td>
<td class="Rrule" align="center">182 (27.1)</td>
<td class="Rrule" align="center">220 (32.6)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hazard ratio<a href="#footnote-11" class="Sup">†</a>  [95% CI]</td>
<td class="Rrule" align="center" colspan="2">0.80 [0.65 , 0.97]</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="3">Stage II (Dukes' B2)</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">N</td>
<td class="Rrule" align="center">451</td>
<td class="Rrule" align="center">448</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> events (%)</td>
<td class="Rrule" align="center">63 (14.0)</td>
<td class="Rrule" align="center">63 (14.1)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Hazard ratio<a href="#footnote-11" class="Sup">†</a>  [95% CI]</td>
<td class="Rrule" align="center" colspan="2">1.00 [0.70 , 1.41]</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Combination Therapy with ELOXATIN and 5-fluorouracil/leucovorin in Patients Previously Untreated for Advanced Colorectal Cancer</h2>
<p class="First">A North American, multicenter, open-label, randomized controlled study was sponsored by the National Cancer Institute (NCI) as an intergroup study led by the North Central Cancer Treatment Group (NCCTG). The study had 7 arms at different times during its conduct, four of which were closed due to either changes in the standard of care, toxicity, or simplification. During the study, the control arm was changed to irinotecan plus 5-fluorouracil/leucovorin. The results reported below compared the efficacy and safety of two experimental regimens, ELOXATIN in combination with infusional 5-fluorouracil/leucovorin and a combination of ELOXATIN plus irinotecan, to an approved control regimen of irinotecan plus 5-fluorouracil/leucovorin in 795 concurrently randomized patients previously untreated for locally advanced or metastatic colorectal cancer. After completion of enrollment, the dose of irinotecan plus 5-fluorouracil/leucovorin was decreased due to toxicity. Patients had to be at least 18 years of age, have known locally advanced, locally recurrent, or metastatic colorectal adenocarcinoma not curable by surgery or amenable to radiation therapy with curative intent, histologically proven colorectal adenocarcinoma, measurable or evaluable disease, with an ECOG performance status 0,1, or 2. Patients had to have granulocyte count ≥ 1.5 × 10<span class="Sup">9</span>/L, platelets ≥ 100 × 10<span class="Sup">9</span>/L, hemoglobin ≥9.0 gm/dL, creatinine ≤ 1.5 × ULN, total bilirubin ≤ 1.5 mg/dL, AST ≤ 5 × ULN, and alkaline phosphatase ≤ 5 × ULN. Patients may have received adjuvant therapy for resected Stage II or III disease without recurrence within 12 months. The patients were stratified for ECOG performance status (0, 1 vs. 2), prior adjuvant chemotherapy (yes vs. no), prior immunotherapy (yes vs. no), and age (&lt;65 vs. ≥65 years). Although no post study treatment was specified in the protocol, 65 to 72% of patients received additional post study chemotherapy after study treatment discontinuation on all arms. Fifty-eight percent of patients on the ELOXATIN plus 5-fluorouracil/leucovorin arm received an irinotecan-containing regimen and 23% of patients on the irinotecan plus 5-fluorouracil/leucovorin arm received oxaliplatin-containing regimens. Oxaliplatin was not commercially available during the trial.</p>
<p>The following table presents the dosing regimens of the three arms of the study.</p>
<table width="75%">
<caption><span>Table 20 – Dosing Regimens in Patients Previously Untreated for Advanced Colorectal Cancer Clinical Trial</span></caption>
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Treatment Arm</th>
<th class="Rrule" align="center">Dose</th>
<th class="Rrule" align="center">Regimen</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">ELOXATIN +<br>5-FU/LV<br>(FOLFOX4)<br>(N=267)</td>
<td class="Rrule" align="center">Day 1:  ELOXATIN: 85 mg/m<span class="Sup">2</span> (2-hour infusion) + LV 200 mg/m<span class="Sup">2</span> (2-hour infusion), followed by<br>5-FU:  400 mg/m<span class="Sup">2</span> (bolus), 600 mg/m<span class="Sup">2</span> (22-hour infusion)<br><br>Day 2:  LV 200 mg/m<span class="Sup">2</span> (2-hour infusion), followed by<br>5-FU:  400 mg/m<span class="Sup">2</span> (bolus), 600 mg/m<span class="Sup">2</span> (22-hour infusion)</td>
<td class="Rrule" align="center">every 2 weeks</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Irinotecan +<br>5-FU/LV<br>(IFL)<br>(N=264)</td>
<td class="Rrule" align="left">Day 1: irinotecan 125 mg/m<span class="Sup">2</span> as a 90–min infusion +<br>LV 20 mg/m<span class="Sup">2</span> as a 15-min infusion or intravenous push, followed by<br>5-FU 500 mg/m<span class="Sup">2</span> intravenous  bolus weekly × 4</td>
<td class="Rrule" align="center">every 6 weeks</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">ELOXATIN +<br>Irinotecan<br>(IROX)<br>(N=264)</td>
<td class="Rrule" align="left">Day 1: ELOXATIN: 85 mg/m<span class="Sup">2</span> intravenous  (2-hour infusion) +<br>irinotecan 200 mg/m<span class="Sup">2</span> intravenous  over 30 minutes</td>
<td class="Rrule" align="center">every 3 weeks</td>
</tr>
</tbody>
</table>
<p>The following table presents the demographics of the patient population entered into this study.</p>
<table width="75%">
<caption><span>Table 21 – Patient Demographics in Patients Previously Untreated for Advanced Colorectal Cancer Clinical Trial</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">ELOXATIN + 5-FU/LV<br>N=267</th>
<th class="Rrule" align="center">Irinotecan + 5-FU/LV<br>N=264</th>
<th class="Rrule" align="center">ELOXATIN + irinotecan<br>N=264</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Sex:  Male (%)</td>
<td class="Rrule" align="center">58.8</td>
<td class="Rrule" align="center">65.2</td>
<td class="Rrule" align="center">61.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">        Female (%)</td>
<td class="Rrule" align="center">41.2</td>
<td class="Rrule" align="center">34.8</td>
<td class="Rrule" align="center">39.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Median age (years)</td>
<td class="Rrule" align="center">61.0</td>
<td class="Rrule" align="center">61.0</td>
<td class="Rrule" align="center">61.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">&lt;65 years of age (%)</td>
<td class="Rrule" align="center">61</td>
<td class="Rrule" align="center">62</td>
<td class="Rrule" align="center">63</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">≥65 years of age (%)</td>
<td class="Rrule" align="center">39</td>
<td class="Rrule" align="center">38</td>
<td class="Rrule" align="center">37</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">ECOG (%)</td>
<td align="center"></td>
<td align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">0.1</td>
<td class="Rrule" align="center">94.4</td>
<td class="Rrule" align="center">95.5</td>
<td class="Rrule" align="center">94.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">2</td>
<td class="Rrule" align="center">5.6</td>
<td class="Rrule" align="center">4.5</td>
<td class="Rrule" align="center">5.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Involved organs (%)</td>
<td align="center"></td>
<td align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Colon only</td>
<td class="Rrule" align="center">0.7</td>
<td class="Rrule" align="center">0.8</td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Liver only</td>
<td class="Rrule" align="center">39.3</td>
<td class="Rrule" align="center">44.3</td>
<td class="Rrule" align="center">39.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Liver + other</td>
<td class="Rrule" align="center">41.2</td>
<td class="Rrule" align="center">38.6</td>
<td class="Rrule" align="center">40.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Lung only</td>
<td class="Rrule" align="center">6.4</td>
<td class="Rrule" align="center">3.8</td>
<td class="Rrule" align="center">5.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Other (including lymph nodes)</td>
<td class="Rrule" align="center">11.6</td>
<td class="Rrule" align="center">11.0</td>
<td class="Rrule" align="center">12.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Not reported</td>
<td class="Rrule" align="center">0.7</td>
<td class="Rrule" align="center">1.5</td>
<td class="Rrule" align="center">1.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Prior radiation (%)</td>
<td class="Rrule" align="center">3.0</td>
<td class="Rrule" align="center">1.5</td>
<td class="Rrule" align="center">3.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Prior surgery (%)</td>
<td class="Rrule" align="center">74.5</td>
<td class="Rrule" align="center">79.2</td>
<td class="Rrule" align="center">81.8</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Prior adjuvant (%)</td>
<td class="Rrule" align="center">15.7</td>
<td class="Rrule" align="center">14.8</td>
<td class="Rrule" align="center">15.2</td>
</tr>
</tbody>
</table>
<p>The length of a treatment cycle was 2 weeks for the ELOXATIN and 5-fluorouracil/leucovorin regimen; 6 weeks for the irinotecan plus 5-fluorouracil/leucovorin regimen; and 3 weeks for the ELOXATIN plus irinotecan regimen. The median number of cycles administered per patient was 10 (23.9 weeks) for the ELOXATIN and 5-fluorouracil/leucovorin regimen, 4 (23.6 weeks) for the irinotecan plus 5-fluorouracil/leucovorin regimen, and 7 (21.0 weeks) for the ELOXATIN plus irinotecan regimen. Patients treated with the ELOXATIN and 5-fluorouracil/leucovorin combination had a significantly longer time to <span class="product-label-link" type="condition" conceptid="4168352" conceptname="Tumor progression">tumor progression</span> based on investigator assessment, longer overall survival, and a significantly higher confirmed response rate based on investigator assessment compared to patients given irinotecan plus 5-fluorouracil/leucovorin. The following table summarizes the efficacy results.</p>
<table width="75%">
<caption><span>Table 22 – Summary of Efficacy<a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">ELOXATIN + 5-FU/LV<br>N=267</th>
<th class="Rrule" align="center">irinotecan + 5-FU/LV<br>N=264</th>
<th class="Rrule" align="center">ELOXATIN + irinotecan<br>N=264</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>The numbers in the response rate and TTP analysis are based on unblinded investigator assessment.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">†</a></dt>
<dd>Compared to irinotecan plus 5-fluorouracil/leucovorin (IFL) arm</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">‡</a></dt>
<dd>A hazard ratio of less than 1.00 favors Eloxatin + Infusional 5-fluorouracil/leucovorin</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">§</a></dt>
<dd>Based on all patients with measurable disease at baseline</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Survival (ITT)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> N (%)</td>
<td class="Rrule" align="center">155 (58.1)</td>
<td class="Rrule" align="center">192 (72.7)</td>
<td class="Rrule" align="center">175 (66.3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Median survival (months)</td>
<td class="Rrule" align="center">19.4</td>
<td class="Rrule" align="center">14.6</td>
<td class="Rrule" align="center">17.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Hazard Ratio and (95% confidence interval)</td>
<td class="Rrule" align="center">0.65 (0.53–0.80)<a name="footnote-reference-11" href="#footnote-11" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="right">P-value</td>
<td class="Rrule" align="center">&lt;0.0001<a href="#footnote-11" class="Sup">†</a>
</td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">-</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">TTP (ITT, investigator assessment)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Percentage of progressors</td>
<td class="Rrule" align="center">82.8</td>
<td class="Rrule" align="center">81.8</td>
<td class="Rrule" align="center">89.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Median TTP (months)</td>
<td class="Rrule" align="center">8.7</td>
<td class="Rrule" align="center">6.9</td>
<td class="Rrule" align="center">6.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hazard Ratio and (95% confidence interval)<a name="footnote-reference-12" href="#footnote-12" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">0.74 (0.61–0.89)<a href="#footnote-11" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">P-value</td>
<td class="Rrule" align="center">0.0014<a href="#footnote-11" class="Sup">†</a>
</td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">- </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Response Rate (investigator assessment)<a name="footnote-reference-13" href="#footnote-13" class="Sup">§</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Patients with measurable disease</td>
<td class="Rrule" align="center">210</td>
<td class="Rrule" align="center">212</td>
<td class="Rrule" align="center">215</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Complete response N (%)</td>
<td class="Rrule" align="center">13 (6.2)</td>
<td class="Rrule" align="center">5 (2.4)</td>
<td class="Rrule" align="center">7 (3.3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Partial response N (%)</td>
<td class="Rrule" align="center">82 (39.0)</td>
<td class="Rrule" align="center">64 (30.2)</td>
<td class="Rrule" align="center">67 (31.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Complete and partial response N (%)</td>
<td class="Rrule" align="center">95 (45.2)</td>
<td class="Rrule" align="center">69 (32.5)</td>
<td class="Rrule" align="center">74 (34.4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">95% confidence interval</td>
<td class="Rrule" align="center">(38.5 – 52.0)</td>
<td class="Rrule" align="center">(26.2 – 38.9)</td>
<td class="Rrule" align="center">(28.1 – 40.8)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">P-value</td>
<td class="Rrule" align="center">0.0080<a href="#footnote-11" class="Sup">†</a>
</td>
<td class="Rrule" align="center">-</td>
<td class="Rrule" align="center">- </td>
</tr>
</tbody>
</table>
<p>Figure 4 illustrates the Kaplan-Meier survival curves for the comparison of ELOXATIN and 5-fluorouracil/leucovorin combination and ELOXATIN plus irinotecan to irinotecan plus 5-fluorouracil/leucovorin.</p>
<div class="Figure">
<img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3c740b43-f396-4998-bc66-6964a21f7161&amp;name=eloxatin-05.jpg"><p class="MultiMediaCaption">Figure 4– Kaplan-Meier Overall Survival by treatment arm</p>
</div>
<p>A descriptive subgroup analysis demonstrated that the improvement in survival for ELOXATIN plus 5-fluorouracil/leucovorin compared to irinotecan plus 5-fluorouracil/leucovorin appeared to be maintained across age groups, prior adjuvant therapy, and number of organs involved. An estimated survival advantage in ELOXATIN plus 5-fluorouracil/leucovorin versus irinotecan plus 5-fluorouracil/leucovorin was seen in both genders; however it was greater among women than men. Insufficient subgroup sizes prevented analysis by race.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.3"></a><p></p>
<h2>14.3 Combination Therapy with ELOXATIN and 5-fluorouracil/leucovorin in Previously Treated Patients with Advanced Colorectal Cancer</h2>
<p class="First">A multicenter, open-label, randomized, three-arm controlled study was conducted in the US and Canada comparing the efficacy and safety of ELOXATIN in combination with an infusional schedule of 5-fluorouracil/leucovorin to the same dose and schedule of 5-fluorouracil/leucovorin alone and to single agent oxaliplatin in patients with advanced colorectal cancer who had relapsed/progressed during or within 6 months of first-line therapy with bolus 5-fluorouracil/leucovorin and irinotecan. The study was intended to be analyzed for response rate after 450 patients were enrolled. Survival will be subsequently assessed in all patients enrolled in the completed study. Accrual to this study is complete, with 821 patients enrolled. Patients in the study had to be at least 18 years of age, have unresectable, measurable, histologically proven colorectal adenocarcinoma, with a Karnofsky performance status &gt;50%. Patients had to have <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>(AST) and SGPT(ALT) ≤2× the institution's upper limit of normal (ULN), unless liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> were present and documented at baseline by CT or MRI scan, in which case ≤5× ULN was permitted. Patients had to have alkaline phosphatase ≤2× the institution's ULN, unless liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> were present and documented at baseline by CT or MRI scan, in which cases ≤5× ULN was permitted. Prior radiotherapy was permitted if it had been completed at least 3 weeks before randomization. <br>The dosing regimens of the three arms of the study are presented in the table below.</p>
<table width="75%">
<caption><span>Table 23 – Dosing Regimens in Refractory and Relapsed Colorectal Cancer Clinical Trial</span></caption>
<col align="center" valign="top" width="30%">
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center">Treatment</th>
<th class="Rrule" align="left"></th>
<th class="Rrule" align="center"></th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Arm</th>
<th class="Rrule" align="center" valign="bottom">Dose</th>
<th class="Rrule" align="center" valign="bottom">Regimen</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="center">
<br>ELOXATIN +<br>5-FU/LV<br>(N =152)</td>
<td class="Rrule" align="left">Day 1:  ELOXATIN:  85 mg/m<span class="Sup">2</span> (2-hour infusion) + LV  200 mg/m<span class="Sup">2 </span> (2-hour infusion), followed by 5-FU:  400 mg/m<span class="Sup">2</span> (bolus), 600 mg/m<span class="Sup">2</span> (22-hour infusion)<br><br>Day 2: LV  200 mg/m<span class="Sup">2 </span> (2-hour infusion), followed by 5-FU:  400 mg/m<span class="Sup">2</span> (bolus), 600 mg/m<span class="Sup">2</span> (22-hour infusion)</td>
<td class="Rrule" align="center">every 2 weeks</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center">
<br> 5-FU/LV<br>(N=151)</td>
<td class="Rrule Toprule" align="left">Day 1: LV 200 mg/m<span class="Sup">2 </span> (2-hour infusion), followed by 5-FU:  400 mg/m<span class="Sup">2</span> (bolus), 600 mg/m<span class="Sup">2</span> (22-hour infusion)<br><br>Day 2: LV 200 mg/m<span class="Sup">2 </span> (2-hour infusion), followed by 5-FU: 400 mg/m<span class="Sup">2</span> (bolus), 600 mg/m<span class="Sup">2</span> (22-hour infusion)</td>
<td class="Rrule Toprule" align="center">every 2 weeks</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="center">ELOXATIN<br>(N=156)</td>
<td class="Rrule Toprule" align="left">Day 1: ELOXATIN 85 mg/m<span class="Sup">2</span> (2-hour infusion) </td>
<td class="Rrule Toprule" align="center">every 2 weeks</td>
</tr>
</tbody>
</table>
<p>Patients entered into the study for evaluation of response must have had at least one unidimensional lesion measuring ≥20mm using conventional CT or MRI scans, or ≥10mm using a spiral CT scan. Tumor response and progression were assessed every 3 cycles (6 weeks) using the Response Evaluation Criteria in <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">Solid Tumors</span> (RECIST) until radiological documentation of progression or for 13 months following the first dose of study drug(s), whichever came first. Confirmed responses were based on two tumor assessments separated by at least 4 weeks. <br>The demographics of the patient population entered into this study are shown in the table below.</p>
<table width="75%">
<caption><span>Table 24 – Patient Demographics in Refractory and Relapsed Colorectal Cancer Clinical Trial</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">5-FU/LV<br>(N = 151)</th>
<th class="Rrule" align="center">ELOXATIN<br>(N = 156)</th>
<th class="Rrule" align="center">ELOXATIN + 5-FU/LV<br>(N = 152)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Sex:  Male (%)</td>
<td class="Rrule" align="center">54.3</td>
<td class="Rrule" align="center">60.9</td>
<td class="Rrule" align="center">57.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">        Female (%)</td>
<td class="Rrule" align="center">45.7</td>
<td class="Rrule" align="center">39.1</td>
<td class="Rrule" align="center">42.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Median age (years)</td>
<td class="Rrule" align="center">60.0</td>
<td class="Rrule" align="center">61.0</td>
<td class="Rrule" align="center">59.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Range</td>
<td class="Rrule" align="center">21–80</td>
<td class="Rrule" align="center">27–79</td>
<td class="Rrule" align="center">22–88</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4">Race (%)</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Caucasian</td>
<td class="Rrule" align="center">87.4</td>
<td class="Rrule" align="center">84.6</td>
<td class="Rrule" align="center">88.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Black</td>
<td class="Rrule" align="center">7.9</td>
<td class="Rrule" align="center">7.1</td>
<td class="Rrule" align="center">5.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Asian</td>
<td class="Rrule" align="center">1.3</td>
<td class="Rrule" align="center">2.6</td>
<td class="Rrule" align="center">2.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Other</td>
<td class="Rrule" align="center">3.3</td>
<td class="Rrule" align="center">5.8</td>
<td class="Rrule" align="center">2.6</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4">KPS (%)</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  70 – 100</td>
<td class="Rrule" align="center">94.7</td>
<td class="Rrule" align="center">92.3</td>
<td class="Rrule" align="center">95.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  50 – 60</td>
<td class="Rrule" align="center">2.6</td>
<td class="Rrule" align="center">4.5</td>
<td class="Rrule" align="center">2.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Not reported</td>
<td class="Rrule" align="center">2.6</td>
<td class="Rrule" align="center">3.2</td>
<td class="Rrule" align="center">2.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Prior radiotherapy (%)</td>
<td class="Rrule" align="center">25.2</td>
<td class="Rrule" align="center">19.2</td>
<td class="Rrule" align="center">25.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Prior pelvic radiation (%)</td>
<td class="Rrule" align="center">18.5</td>
<td class="Rrule" align="center">13.5</td>
<td class="Rrule" align="center">21.1</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4">Number of metastatic sites (%)</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  1</td>
<td class="Rrule" align="center">27.2</td>
<td class="Rrule" align="center">31.4</td>
<td class="Rrule" align="center">25.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  ≥2</td>
<td class="Rrule" align="center">72.2</td>
<td class="Rrule" align="center">67.9</td>
<td class="Rrule" align="center">74.3</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4">Liver involvement (%)</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Liver only</td>
<td class="Rrule" align="center">22.5</td>
<td class="Rrule" align="center">25.6</td>
<td class="Rrule" align="center">18.4</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Liver + other</td>
<td class="Rrule" align="center">60.3</td>
<td class="Rrule" align="center">59.0</td>
<td class="Rrule" align="center">53.3</td>
</tr>
</tbody>
</table>
<p>The median number of cycles administered per patient was 6 for the ELOXATIN and 5-fluorouracil/leucovorin combination and 3 each for 5-fluorouracil/leucovorin alone and ELOXATIN alone.</p>
<p>Patients treated with the combination of ELOXATIN and 5-fluorouracil/leucovorin had an increased response rate compared to patients given 5-fluorouracil/leucovorin or oxaliplatin alone. The efficacy results are summarized in the tables below.</p>
<table width="75%">
<caption><span>Table 25 - Response Rates (ITT Analysis)</span></caption>
<col align="center" valign="top" width="27%">
<col align="center" valign="top" width="23%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Best Response</th>
<th class="Rrule" align="center">5-FU/LV<br>(N=151)</th>
<th class="Rrule" align="center">ELOXATIN<br>(N=156)</th>
<th class="Rrule" align="center">ELOXATIN + 5-FU/LV<br>(N=152)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">CR</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">PR</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2 (1%)</td>
<td class="Rrule" align="center">13 (9%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">p-value</td>
<td class="Rrule" align="center" colspan="3">0.0002 for 5-FU/LV vs. ELOXATIN + 5-FU/LV</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">95%CI</td>
<td class="Rrule" align="center">0–2.4%</td>
<td class="Rrule" align="center">0.2–4.6%</td>
<td class="Rrule" align="center">4.6–14.2%</td>
</tr>
</tbody>
</table>
<table width="75%">
<caption><span>Table 26 - Summary of Radiographic Time to Progression<a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="23%">
<col align="center" valign="top" width="22%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="bottom">Arm</th>
<th class="Rrule" align="center">5-FU/LV<br>(N=151)</th>
<th class="Rrule" align="center">ELOXATIN<br>(N=156)</th>
<th class="Rrule" align="center">ELOXATIN + 5-FU/LV<br>(N=152)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>This is not an ITT analysis. Events were limited to radiographic disease progression documented by independent review of radiographs. Clinical progression was not included in this analysis, and 18% of patients were excluded from the analysis based on unavailability of the radiographs for independent review.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">No. of Progressors</td>
<td class="Rrule" align="center">74</td>
<td class="Rrule" align="center">101</td>
<td class="Rrule" align="center">50</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">No. of patients with no radiological evaluation beyond baseline</td>
<td class="Rrule" align="center">22<br> (15%)</td>
<td class="Rrule" align="center">16<br> (10%)</td>
<td class="Rrule" align="center">17<br> (11%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Median TTP (months)</td>
<td class="Rrule" align="center">2.7</td>
<td class="Rrule" align="center">1.6</td>
<td class="Rrule" align="center">4.6</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">95% CI</td>
<td class="Rrule" align="center">1.8–3.0</td>
<td class="Rrule" align="center">1.4–2.7</td>
<td class="Rrule" align="center">4.2–6.1</td>
</tr>
</tbody>
</table>
<p>At the time of the interim analysis 49% of the radiographic progression events had occurred. In this interim analysis an estimated 2-month increase in median time to radiographic progression was observed compared to 5-fluorouracil/leucovorin alone.</p>
<p>Of the 13 patients who had tumor response to the combination of ELOXATIN and 5-fluorouracil/leucovorin, 5 were female and 8 were male, and responders included patients &lt;65 years old and ≥65 years old. The small number of non-Caucasian participants made efficacy analyses in these populations uninterpretable.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<ol>
<li>NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004–165.</li>
<li>OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html</li>
<li>American Society of Health-System Pharmacists. (2006) ASHP Guidelines on Handling Hazardous Drugs.</li>
<li>Polovich, M., White, J. M., &amp; Kelleher, L.O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd. ed.) Pittsburgh, PA: Oncology Nursing Society.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<h1>16. HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1"></a><p></p>
<h2>16.1	How Supplied</h2>
<p class="First">ELOXATIN is supplied in clear, glass, single-use vials with gray elastomeric stoppers and aluminum flip-off seals containing 50 mg or 100 mg of oxaliplatin as a sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL.  Water for Injection, USP is present as an inactive ingredient.</p>
<br><p>NDC 0024-0590-10: 50 mg single-use vial with green flip-off seal individually packaged in a carton.</p>
<br><p>NDC 0024-0591-20: 100 mg single-use vial with dark blue flip-off seal individually packaged in a carton.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.2"></a><p></p>
<h2>16.2 Storage</h2>
<p class="First">Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). Do not freeze and protect from light (keep in original outer carton).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.3"></a><p></p>
<h2>16.3 Handling and Disposal</h2>
<p class="First">As with other potentially toxic anticancer agents, care should be exercised in the handling and preparation of infusion solutions prepared from ELOXATIN. The use of gloves is recommended. If a solution of ELOXATIN contacts the skin, wash the skin immediately and thoroughly with soap and water. If ELOXATIN contacts the mucous membranes, flush thoroughly with water.</p>
<p>Procedures for the handling and disposal of anticancer drugs should be considered. Several guidelines on the subject have been published <span class="Italics">[see <a href="#S15">References (15)</a>]</span>. There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise patients:</p>
<ul class="Disc">
<li>To expect side effects of ELOXATIN, particularly its neurologic effects, both the acute, reversible effects and the persistent neurosensory toxicity. Patients should be informed that the acute neurosensory toxicity may be precipitated or exacerbated by exposure to <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> objects.</li>
<li>To avoid <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> drinks, use of ice, and should cover exposed skin prior to exposure to <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> temperature or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> objects.</li>
<li>Of the risk of low blood cell counts and to contact their physician immediately should <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, particularly if associated with persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or evidence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> develop.</li>
<li>To contact their physician if <span class="product-label-link" type="condition" conceptid="27321" conceptname="Persistent vomiting">persistent vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, signs of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> or breathing difficulties occur, or signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> appear.</li>
<li>To exercise caution when driving and using machines. No studies on the effects of the ability to operate cars and machines have been performed; however, oxaliplatin treatment resulting in an increase risk of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and other <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic symptoms</span> that affect gait and balance may lead to a minor or moderate influence on the ability to drive and use machines.</li>
<li>Of the potential effects of vision abnormalities, in particular transient <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span> (reversible following therapy discontinuation), which may affect patients' ability to drive and use machines.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Patient Information</span></p>
<p><span class="Bold">ELOXATIN<span class="Sup">®</span></span> (eh-LOX-ah-tin)<span class="Bold"><br>(OXALIplatin) <br>concentrate, for solution for intravenous use</span></p>
<br><br><p>Read this Patient Information leaflet carefully before you start receiving ELOXATIN. There may be new information. It will help you learn more about ELOXATIN. This leaflet does not take the place of talking to your doctor about your medical condition or your treatment. Ask your doctor about any questions you have.</p>
<br><p><span class="Bold">What is the most important information I should know about ELOXATIN? </span></p>
<p><span class="Bold">Serious side effects can happen in people taking ELOXATION, including:</span></p>
<ul class="Disc"><li>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>. ELOXATIN can cause serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> that may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </span>ELOXATIN is a platinum base medicine. Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> can occur in people who take Eloxatin and who have had previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to platinum medicines. Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> can happen within a few minutes of your infusion or any time during your treatment with ELOXATIN.</li></ul>
<p><span class="Bold">Get emergency help right away if you:</span></p>
<ul>
<li>
<span class="Bold">have trouble breathing</span>.</li>
<li><span class="Bold">feel like your throat is closing up.</span></li>
</ul>
<p>Call your doctor right away if you have any of the following signs or symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed face</span></li>
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span></li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your lips or tongue</li>
<li>sudden <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span></li>
<li><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
</ul>
<p><span class="Bold">See "What are the possible side effects of ELOXATIN?" for information about other serious side effects. </span></p>
<br><p><span class="Bold">What is ELOXATIN?</span></p>
<p>ELOXATIN is an anti-cancer (chemotherapy) medicine that is used with other anti-cancer medicines called 5-fluorouracil and leucovorin to treat people with:</p>
<ul>
<li>stage III colon cancer after surgery to remove the tumor</li>
<li>advanced colon or rectal cancer (colo-rectal cancer).</li>
</ul>
<p>ELOXATIN with infusional 5-fluorouracil and leucovorin was shown to lower the chance of colon cancer returning when given to patients with stage III colon cancer after surgery to remove the tumor. ELOXATIN also increases survival in patients with stage III colon cancer. ELOXATIN with infusional 5-fluorouracil and leucovorin was also shown to increase survival, shrink tumors and delay growth of tumors in some patients with advanced colorectal cancer. </p>
<p>It is not known if ELOXATIN works in children. </p>
<br><p><span class="Bold">Who should not use ELOXATIN?</span></p>
<ul class="Disc"><li>Do not use ELOXATIN if you are allergic to any of the ingredients in ELOXATIN or other medicines that contain platinum. Cisplatin and carboplatin are other chemotherapy medicines that also contain platinum. See the end of this leaflet for a complete list of the ingredients ELOXATIN.</li></ul>
<p>Ask your doctor if you are not sure if you take a medicine that contains platinum.</p>
<p><span class="Bold">What should I tell my doctor before treatment with ELOXATIN? </span><span class="Bold"><br>Before receiving ELOXATIN, tell your doctor </span>if you: </p>
<ul>
<li>have kidney problems </li>
<li>have any other medical conditions</li>
<li>have had any <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to any medicines</li>
<li>are pregnant or plan to become pregnant. ELOXATIN may harm your unborn child. You should avoid becoming pregnant while taking ELOXATIN. Talk with your doctor about how to avoid pregnancy. </li>
<li>are breastfeeding or plan to breastfeed. It is not known if ELOXATIN passes into your breast milk. You and your doctor should decide whether you will stop breastfeeding or not take ELOXATIN. </li>
</ul>
<p>Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.<br>Know the medicines you take.  Keep a list of them and show it to your doctor and pharmacist when you get a new medicine. 	</p>
<br><p><span class="Bold">How is ELOXATIN given to me?</span></p>
<p>ELOXATIN is given to you through your veins (blood vessels).</p>
<p>•	Your doctor will prescribe ELOXATIN in an amount that is right for you.  <br>•	Your doctor will treat you with several medicines for your cancer. <br> •	It is very important that you do exactly what your doctor and nurse have taught you to do.  <br>•	Some medicines may be given to you before ELOXATIN to help prevent <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.  <br>•	ELOXATIN is given with 2 other chemotherapy medicines, leucovorin and 5-fluorouracil.  <br>•	Each treatment course is given to you over 2 days. You will receive ELOXATIN on the first day only.  <br>•	There are usually 14 days between each chemotherapy treatment course. </p>
<p><span class="Bold Underline">Treatment Day 1: </span></p>
<p>ELOXATIN and leucovorin are given through a thin plastic tube put into a vein (intravenous infusion or I.V.) and given for 2 hours. You will be watched by a healthcare provider during this time. </p>
<p>Right after the ELOXATIN and leucovorin are finished, 2 doses of 5-fluorouracil will be given. The first dose is given right away into your I.V. tube. The second dose will be given into your I.V. tube over the next 22 hours, using a pump device.</p>
<p><span class="Bold Underline">Treatment Day 2:</span></p>
<p>You will not get ELOXATIN on Day 2. Leucovorin and 5-fluorouracil will be given the same way as on Day 1. </p>
<br><p><span class="Bold">During your treatment with ELOXATIN:</span></p>
<ul>
<li>It is important for you to keep all appointments. Call your doctor if you must miss an appointment. There may be special instructions for you.</li>
<li>Your doctor may change how often you get ELOXATIN, how much you get, or how long the infusion will take.</li>
<li>You and your doctor will discuss how many times you will get ELOXATIN.</li>
</ul>
<p>The 5-fluorouracil will be given through your I.V. with a pump. If you have any problems with the pump or the tube, call your doctor, your nurse, or the person who is responsible for your pump. Do not let anyone other than a healthcare provider touch your infusion pump or tubing.</p>
<p><span class="Bold">What activities should I avoid while on treatment with ELOXATIN?</span></p>
<ul>
<li>Avoid <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> temperatures and <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> objects. Cover your skin if you must go outside in <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> temperatures.</li>
<li>Do not drink <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> drinks or use ice cubes in drinks.</li>
<li>Do not put ice or ice packs on your body.</li>
</ul>
<p>See "How can I reduce the side effects caused by <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> temperatures?" for more information.</p>
<p>Talk with your doctor and nurse about your level of activity during treatment with ELOXATIN. <br>Follow their instructions.</p>
<br><p><span class="Bold">What are the possible side effects of ELOXATIN</span>?</p>
<p>ELOXATIN can cause serious side effects, including:</p>
<ul>
<li>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</span> See "What is the most important information I should know about ELOXATIN?" </li>
<li>
<span class="Bold">Nerve problems.</span>  ELOXATIN can affect how your nerves work and make you feel. Tell your doctor right away if you get any signs of nerve problems listed below: <dl>
<dt>▪</dt>
<dd>very sensitive to <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> temperatures and <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> objects </dd>
<dt>▪</dt>
<dd>trouble breathing, swallowing, or saying words, jaw tightness, odd feelings in your tongue, or <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest pressure</span></dd>
<dt>▪</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, burning (pins and needles, numb feeling) in your hands, feet, or around your mouth or throat, which may cause problems walking or performing activities of daily living.  </dd>
</dl>
</li>
<li>
<span class="Bold">Reversible Posterior <span class="product-label-link" type="condition" conceptid="4027461" conceptname="Leukoencephalopathy">Leukoencephalopathy</span> (RPLS). </span>RPLS is a rare condition that affects the brain.  Tell your doctor right away if you have any of the following signs and symptoms of RPLS:<dl class="Disc">
<dt>▪</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
<dt>▪</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> or a change in the way you think</dd>
<dt>▪</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></dd>
<dt>▪</dt>
<dd>vision problems, such as blurriness or <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>. You should not drive, operate heavy machines, or engage in dangerous activities if you have vision problems while receiving ELOXATIN.</dd>
</dl>
</li>
</ul>
<dl>
<dd></dd>
<dt>The first signs of nerve problems may happen with the first treatment. The nerve problems can also start up to 2 days after treatment. If you develop nerve problems, the amount of ELOXATIN in your next treatment may be changed or ELOXATIN treatment may be stopped. </dt>
<dd></dd>
<dd>
<br><br>
</dd>
<dt>For information on ways to lessen or help with the nerve problems, see the end of this leaflet, "How can I reduce the side effects caused by <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> temperatures?" </dt>
<dd></dd>
<dd></dd>
<dd></dd>
<dd>
<br><br>
</dd>
</dl>
<ul class="Disc">
<li>
<span class="Bold">Lung problems (interstitial <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>).</span>  Tell your doctor right away if you get a <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">dry cough</span> and have trouble breathing (<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>) before your next treatment. These may be signs of a serious <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>.</li>
<li>
<span class="Bold">Liver problems (hepatotoxicity).</span>  Your doctor will do blood tests to check your liver.</li>
<li>
<span class="Bold">Harm to an unborn baby.  ELOXATIN may cause harm to your unborn baby. </span> See "What should I tell my doctor before treatment with ELOXATIN?" </li>
</ul>
<br><br><p>The most common side effects of ELOXATIN include: </p>
<ul>
<li>Decreased blood counts: ELOXATIN can cause a decrease in <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> (a type of white blood cells important in fighting <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>), red blood cells (blood cells that carry oxygen to the tissues), and platelets (important for clotting and to control <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>).  </li>
<li>High blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> Call your doctor right away if you get any of the following signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>:<table width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr class="First Last">
<td class="Rrule" align="left"><dl>
<dt>▪</dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (temperature of 100.5 F or greater)</dd>
<dt>▪</dt>
<dd><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span></dd>
<dt>▪</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on swallowing</dd>
<dt>▪</dt>
<dd><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></dd>
</dl></td>
<td align="left"><dl>
<dt>▪</dt>
<dd><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> that brings up mucus</dd>
<dt>▪</dt>
<dd>burning or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on urination</dd>
<dt>▪</dt>
<dd><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> at intravenous site</dd>
</dl></td>
</tr></tbody>
</table>
</li>
</ul>
<br><br><ul class="Dsic">
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>. Tell your doctor about any signs or symptoms of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></li>
<li>Mouth sores</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Tiredness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reactions</span>.  Reactions may include <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, tissue damage at the site of injection. </li>
<li><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair loss</span> (<span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>)</li>
</ul>
<br><ul><li><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span> (too much water loss). Call you doctor if you have signs of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> including:  			<table width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr class="First Last">
<td class="Rrule" align="left"><dl>
<dt>▪</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></dd>
<dt>▪</dt>
<dd><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span> </dd>
<dt>▪</dt>
<dd><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span></dd>
</dl></td>
<td align="left"><dl>
<dt>▪</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> (<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>) </dd>
<dt>▪</dt>
<dd>decreased urination</dd>
</dl></td>
</tr></tbody>
</table>
</li></ul>
<p>Tell your doctor if you have any side effect that bothers your or that does not go away.  These are not all the possible side effects of ELOXATIN. For more information, ask your doctor or pharmacist.   </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<br><p><span class="Bold">How can I reduce the side effects caused by <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> temperatures?</span></p>
<ul>
<li>Cover yourself with a blanket while you are getting your ELOXATIN infusion.</li>
<li>Do not breathe deeply when exposed to <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> air.</li>
<li>Wear warm clothing in <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> weather at all times. Cover your mouth and nose with a scarf or a pull-down cap (ski cap) to warm the air that goes to your lungs.</li>
<li>Wear gloves when taking things from the freezer or refrigerator.</li>
<li>Drink fluids warm or at room temperature.</li>
<li>Always drink through a straw.</li>
<li>
<span class="Bold">Do not</span> use ice chips if you have <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or mouth sores. Ask your healthcare provider or doctor about what you can use.</li>
<li>Be aware that most metals are <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> to touch, especially in the winter. These include your car door and mailbox. Wear gloves to touch <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> objects.</li>
<li>Do not run the air-conditioning at high levels in the house or in the car in hot weather.</li>
<li>If your body gets <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, warm-up the affected part. If your hands get <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, wash them with warm water.</li>
<li>Always let your healthcare provider or doctor know <span class="Bold">before</span> your next treatment how well you did since your last visit.</li>
</ul>
<p>This list is not complete and your healthcare provider or doctor may have other useful tips for helping you with these side effects.</p>
<p><span class="Bold">General information about the safe and effective use of ELOXATIN</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet. </p>
<p>This Patient Information leaflet summarizes the most important information about ELOXATIN. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about ELOXATIN that is written for health professionals.</p>
<br><p><span class="Bold">What are the ingredients in ELOXATIN? </span><br>Active ingredient:  oxaliplatin  </p>
<p>Concentrate for solution for infusion inactive ingredients:  water for injection</p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-18"></a><p></p>
<h1></h1>
<p class="First">Manufactured by:<br>sanofi-aventis U.S. LLC<br>Bridgewater, NJ 08807<br><span class="Bold">A SANOFI COMPANY</span></p>
<p>© 2014 sanofi-aventis U.S. LLC</p>
<p>Revised: February 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 50 mg Carton</span></p>
<p><span class="Bold">NDC </span>0024-0590-10<br><span class="Bold">50 mg</span></p>
<p><span class="Bold Italics">Eloxatin</span><span class="Sup">®</span><br>(<span class="Bold">OXALI</span>platin injection) 5 mg/mL<br><span class="Bold">INJECTION<br>50 mg</span></p>
<p><span class="Bold">FOR INTRAVENOUS USE ONLY<br>SINGLE USE VIAL ONLY</span></p>
<p>Sterile Aqueous Solution - Preservative Free</p>
<p><span class="Bold">See package insert for further<br>required dilution.</span></p>
<p><span class="Bold">DO NOT MIX OR ADD TO<br>SODIUM CHLORIDE/<br>CHLORIDE-CONTAINING<br>SOLUTIONS</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">SANOFI</span></p>
<div class="Figure"><img alt="Principal Display Panel - 50 mg Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3c740b43-f396-4998-bc66-6964a21f7161&amp;name=eloxatin-06.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 100 mg Carton</span></p>
<p><span class="Bold">NDC </span>0024-0591-20<br><span class="Bold">100 mg</span></p>
<p><span class="Bold Italics">Eloxatin</span><span class="Sup">®</span><br>(<span class="Bold">OXALI</span>platin injection) 5 mg/mL<br><span class="Bold">INJECTION<br>100 mg</span></p>
<p><span class="Bold">FOR INTRAVENOUS USE ONLY<br>SINGLE USE VIAL ONLY</span></p>
<p>Sterile Aqueous Solution - Preservative Free</p>
<p><span class="Bold">See package insert for further<br>required dilution.</span></p>
<p><span class="Bold">DO NOT MIX OR ADD TO<br>SODIUM CHLORIDE/<br>CHLORIDE-CONTAINING<br>SOLUTIONS</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">SANOFI</span></p>
<div class="Figure"><img alt="Principal Display Panel - 100 mg Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3c740b43-f396-4998-bc66-6964a21f7161&amp;name=eloxatin-07.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ELOXATIN 		
					</strong><br><span class="contentTableReg">oxaliplatin injection, solution, concentrate</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0024-0590</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>oxaliplatin</strong> (oxaliplatin) </td>
<td class="formItem">oxaliplatin</td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0024-0590-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021759</td>
<td class="formItem">06/02/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ELOXATIN 		
					</strong><br><span class="contentTableReg">oxaliplatin injection, solution, concentrate</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0024-0591</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>oxaliplatin</strong> (oxaliplatin) </td>
<td class="formItem">oxaliplatin</td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0024-0591-20</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021759</td>
<td class="formItem">06/02/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>sanofi-aventis U.S. LLC
							(824676584)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">sanofi-aventis Deutschland GmbH</td>
<td class="formItem"></td>
<td class="formItem">313218430</td>
<td class="formItem">MANUFACTURE(0024-0590, 0024-0591), ANALYSIS(0024-0590, 0024-0591), PACK(0024-0590, 0024-0591), LABEL(0024-0590, 0024-0591)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">sanofi-aventis U.S. LLC</td>
<td class="formItem"></td>
<td class="formItem">011330557</td>
<td class="formItem">LABEL(0024-0590, 0024-0591)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b2765875-6f43-436b-ba0a-acabeaf31461</div>
<div>Set id: 3c740b43-f396-4998-bc66-6964a21f7161</div>
<div>Version: 9</div>
<div>Effective Time: 20140220</div>
</div>
</div> <div class="DistributorName">sanofi-aventis U.S. LLC</div></p>
</body></html>
